IE55793B1 - Use of sugar derivatives for the prophylaxis and treatment of virus infections - Google Patents
Use of sugar derivatives for the prophylaxis and treatment of virus infectionsInfo
- Publication number
- IE55793B1 IE55793B1 IE1728/83A IE172883A IE55793B1 IE 55793 B1 IE55793 B1 IE 55793B1 IE 1728/83 A IE1728/83 A IE 1728/83A IE 172883 A IE172883 A IE 172883A IE 55793 B1 IE55793 B1 IE 55793B1
- Authority
- IE
- Ireland
- Prior art keywords
- formula
- radical
- carbon atoms
- hydroxy
- group
- Prior art date
Links
- 238000011321 prophylaxis Methods 0.000 title claims description 13
- 238000011282 treatment Methods 0.000 title description 11
- 230000009385 viral infection Effects 0.000 title description 4
- -1 iminocarbonyl Chemical group 0.000 claims abstract description 190
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 147
- 239000001257 hydrogen Substances 0.000 claims abstract description 111
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 111
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 107
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 52
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 52
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 52
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 37
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 30
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 22
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 17
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims abstract description 16
- 125000004429 atom Chemical group 0.000 claims abstract description 16
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 14
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 12
- 125000002252 acyl group Chemical group 0.000 claims abstract description 8
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims abstract description 8
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 7
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims abstract description 7
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 claims abstract description 3
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 42
- 125000003282 alkyl amino group Chemical group 0.000 claims description 41
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 41
- 239000001301 oxygen Substances 0.000 claims description 41
- 229910052760 oxygen Inorganic materials 0.000 claims description 41
- 125000001589 carboacyl group Chemical group 0.000 claims description 40
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 37
- 241000700605 Viruses Species 0.000 claims description 36
- 159000000000 sodium salts Chemical class 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 19
- 125000004423 acyloxy group Chemical group 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 5
- 229940100662 nasal drops Drugs 0.000 claims description 5
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- 125000005103 alkyl silyl group Chemical group 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 229940012356 eye drops Drugs 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 229940100657 nasal ointment Drugs 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims 66
- PVRDHKBVCDWVPD-UHFFFAOYSA-N 6,7-Dimethyl-9-(2-acetoxyethyl)isoalloxazine Chemical compound CC(=O)OCCN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O PVRDHKBVCDWVPD-UHFFFAOYSA-N 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 claims 1
- 239000002361 compost Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 239000002253 acid Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- WQZGKKKJIJFFOK-UHFFFAOYSA-N hexopyranose Chemical class OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 15
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- 208000037797 influenza A Diseases 0.000 description 10
- 229920003023 plastic Polymers 0.000 description 10
- 239000004033 plastic Substances 0.000 description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 10
- 206010002091 Anaesthesia Diseases 0.000 description 9
- 239000005662 Paraffin oil Substances 0.000 description 9
- 238000001949 anaesthesia Methods 0.000 description 9
- 230000037005 anaesthesia Effects 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 229960000541 cetyl alcohol Drugs 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 241000700198 Cavia Species 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6
- 229960002216 methylparaben Drugs 0.000 description 6
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 6
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 6
- 229960003415 propylparaben Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 150000002191 fatty alcohols Chemical class 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 229960004274 stearic acid Drugs 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000001587 sorbitan monostearate Substances 0.000 description 4
- 229940035048 sorbitan monostearate Drugs 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 150000000778 D-glucopyranose derivatives Chemical class 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 241000710189 Aphthovirus Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000007765 cera alba Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000700587 Alphaherpesvirinae Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000701021 Betaherpesvirinae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 150000000780 D-glucose derivatives Chemical class 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical compound NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005035 acylthio group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 125000000755 henicosyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. A pharmaceutical composition for enteral or parenteral application, which composition contains, as sole active ingredient, an effective amount, but less than 1 % by weight, of a compound of the formula I see diagramm : EP0102319,P31,F1 in which the sugar moiety is derived from (D)-galactose, (D)-mannose or (D)-glucose, which compound has at an asymmetrically substituted C(-R**3) atom the (D)-configuration, at an asymmetrically substituted C(-R**6) atom the (L)-configuration and at an asymmetrically substituted C(-R**8) atom the (D)-configuration, and in which compound each of X**1 and X**2 independently to the other represents a group of the formula -O- or -N(R**14)-, R**14 representing hydrogen or lower alkyl, each of R**1, R**2, R**12 and R**13 independently represents a radical of the formula Ia -(Z**1-Y**1-X**3)n -A**1 in which n represents 0 or 1, Z**1 represents carbonyl or thiocarbonyl, Y**1 represents unsubstituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, X**3 represents a group of the formula -O- or -N(R**14)-, wherein R**14 has the meaning given above, and A**1 represents a radical of the formula Ib see diagramm : EP0102319,P31,F2 in which R**15 represents an aliphatic or cycloaliphatic radical having at least 7 carbon atoms, or A**1 represents a group of the formula Ic see diagramm : EP0102319,P31,F3 in which R**16 represents hydrogen and R**17 represents 2-hydroxyethyl or 1,2-dihydroxyethyl, wherein at least one hydroxy group is esterified or etherified by a radical having at least 7 carbon atoms, or in which each or R**16 and R**17 independently of the other represents esterified or etherified hydroxymethyl, the esterifying or etherifying radicals having at least 7 carbon atoms, or each of R**1, R**2, R**12 and R**13 independently represents hydrogen, acyl other than a radical of the formula Ia in which n represents 1, or aliphatically substituted silyl, each of R**3, R**4, R**5, R**7 and R**8 independently represents hydrogen or lower alkyl, R**6 represents hydrogen or lower alkyl that is unsubstituted or substituted by a group of the formula Id -E-(Z**2-Y**2-X**4)m -A**2 in which m represents 0 or 1, E represents a group of the formula -O-, -S- or -N(R**14), R**14 having the meaning given above, Z**2 represents carbonyl or thiocarbonyl, Y**2 represents unsubstituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, X**4 represents a group of the formula -O- or -N(R**14)-, having the meaning given above, and A**2 represents a radical of the formula Ib or lc ; or by free or etherified hydroxy or mercapto, by esterified hydroxy or mercapto other than a group of the formula Id, by free amino or substituted amino other than a group of the formula Id, by free, esterified or amidated carboxy, by cycloalkyl, by carbocyclic aryl or by nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring, or R**5 and R**6 together represent unsubstituted 1,3- or 1,4-lower alkylene, each of R**9 and R**11 independently of the other represents a radical of the formula Ie -X**5-Y**3-X**6-A**3 in which X**5 represents a group of the formula -O-, -S- or -N(R**14)-, and X**6 represents a group of the formula -O- or -N(R**14)-, in each case R**14 having the meaning given above, Y**3 represents unsubstituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, and A**3 represents a radical of the formula Id or lc, or free hydroxy or mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or substituted amino other than a radical of the formula Ie, and represents hydrogen or free, esterified or amidated carboxy, with the proviso that radicals qualified by the term "lower" contain up to and including 7 carbon atoms and that the compounds of the formula I have at least one radical A**1, A**2 or A**3 and/or a pharmaceutically acceptable salt thereof, together with a pharmaceutical carrier.
Description
The present invention relates to the use of hexopyranose derivatives, containing a phosphoryl residue and in the 3-position of the sugar moiety a peptidic side chain, for the manufacture of pharmaceutical compositions which are to .be used for the prophylaxis and therapy of diseases caused by viruses, as well as to pharmaceutical compositions containing less than 1 % by weight of such a hexopyranose derivative.
The above-mentioned hexopyranose compounds of the formula I 70 and the salts thereof as well as the manufacture thereof are described in the European patent applications with the publication numbers*0025 495, 0027 258 and 0056 992 which are in . the name of the Applicants of the present invention, and the last-mentioned application was not published until after the priority date of the present application. The use of the phosphoryl muramylpeptides per se for the manufacture of pharmaceutical compositions for the prophylaxis and therapy . of infections caused by viruses is neither described in nor made obvious by the above-mentioned applications.
The penultimate paragraph on page 13 of the above-mentioned application 0025 495 relates only to the use as an adjuvant in admixture with vaccines.
The above-mentioned applications 0025 495 and 0027 258 describe also pharmaceutical compositions which, however, contain about 10 % to about 95 % of an active ingredient. In the above-men tioned application 0056 992 pharmaceutical compositions containing about 1 % to about XOO %, especially about 5 % to about 50 %, of an active ingredient are described.
The task according to the invention was the preparation of pharmaceutical compositions outstandingly suitable for the prophylaxis and therapy of infections caused by viruses in warm-blood animals. lo According to the present application the solution of this task resides in the finding that hexopyranose compounds of the formula I, R13—ΧΟΗ r12-o~> (ΐ) / V-R2 I 4 C-R* C—NII ό 0=C-R9 R10 O I I β N—CH— CH2— CH— C— R in which the sugar moiety is derived from (D)-galactose, (D)-mannose or (D)-glucose, which compound has at an asym3 metrically substituted C(-R ) atom the (D)-configuration, at an asymmetrically substituted C(-R^) atom the (L)-confi8 guration and at an asymmetrically substituted C(-R ) atom the (D)-configuration, and tn which compound each of X1 and 2 X r independently of the other, represents a group of the formula -O- or each of R1, R2, R12 and R15, K(R^)-, r!4 representing hydrogen or lower alkylf Independently of one another, represents a radical of the formula Ia -( X~)n-A (Ia) in which £ represents 0 or 1, represents carbonyl or thiocarbonyl, represents unsubstituted or substituted alkylene which may be interrupted by Iminocarbonyl or oxyx carbonyl, X represents a group of the formula -0or -R(R^)-, wherein R^ has the meaning given above, and A^ represents a radical of the formula lb, II -P-O-R db) OH in which R represents an aliphatic or cycloaliphatic radical having at least 7 carbon atoms, or A^" represents a group of the formula Ic, v O R II I -Ρ - Ο - CH 1 'Χ7 OH RA (Ic) in which iP*® represents hydrogen and R represents 2-hydroxyethyl or 1,2-dihydroxyethyl, wherein at least one hydroxy group is esterified or etherified by a radical having at least 7 carbon atoms, or in which each of fil® and R1*7, independently of the other, represents esterified or etherified hydroxymethyl, the esterifying or etherifying radicals having at .least 7 carbon atoms, or 2 T9 19 each of R , R , R and R , independently of one another, represents hydrogen, acyl other than a radical of the formula Ia in which n represents 1, or aliphatically substituted silyl. each of r\ r\ r\ & R' and R , Independently of one another, represents hydrogen or lower alkyl, . represents hydrogen or lower alkyl that is unsubstituted or substituted by a group of the formula Id, w -β-(ζ2-Y2-X4 )m-A2 (Id) * in which jj represents 0 or 1, E represents a group of the formula -0*. -3- or -41(1.^)-, having the to meaning given above, Z represents carbonyl or thiocarbonyl, X2 represents unsubstituted or substituted alkylene 15 which may be interrupted by iminocarbonyl or oxy* carbonyl, X* represents a group of the formula -0or -H(R14)-, R34 having 2o the meaning given above, and A represents a radical of the formula lb or Io; or by free or etherified hydroxy or mercapto, 25 by esterified hydroxy or mercapto other than a group of the formula Id, by free amino or substituted amino other than a 30 group of the formula Id, by free, esterified or ‘ amidated carboxy, by cycloalkyl, by carbocyclio aryl ΟΓ and Β6 Q 11 each of Br and fi , or by nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring» together represent unsubetituted or substituted lt 3- or 1,4-lower alkylene, independently of the other, represents a radical of the formula Is, -x5-y3-x6-A3 (le) in which represents a group of the formula -0-, —S— or —fi(fi^)—, and X® represents a group of the formula -0- or -fi(fi^)-, in each case fi^ having the meaning given above, T? represents unsubatituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, and A? represents a radical of the formula Ib or Ic, or free hydroxy or mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or substituted amino other than a radical of the formula Ie, and represents hydrogen or free» esterified or amidated carboxy, with the proviso that radicals qualified by the term lower contain up to and including 7 carbon atoms and that the cons1 2 pounds of the formula I have at least one radical A , A or 3 A , and pharmaceutically acceptable salts of such compounds are suitable for the manufacture of pharmaceutical compositions to be used for the prophylaxis and (preferably) treatment of virus infections in warm-blooded animals, especially and including humans. 4.
By contrast with the treatment of bacterial infections, agents available for the prophylaxis and treatment of virus infections are few and inadequate so that to overcome viral diseases it is in almost all cases necessary that the organism itself has adequate powers of defence· In accordance with the invention It has surprisingly been found that the above-mentioned hexopyranose compounds of the formula I and their pharmaceutically acceptable salts are excellently suitable both for the prophylaxis and treatment of virus infections, as demonstrated, for example, by animal experiments such as those illustrated in the Examples. In these animal experiments animals, such as mice or guinea pigs, are infected by a vide variety of types of virus in a dose that is lethal for all or the large majority of untreated (control) animals, for example ^gQ_goe ***& the course of the infection -is observed in the untreated control animals compared with animals that are treated before, at the same time as, or after the infection, with one of the above-mentioned hexopyranose compounds or a salt thereof.
These experiments demonstrate that the antiviral action of the above-mentioned hexopyranose compounds of the formula I and their salts is not achieved by any hitherto known antiviral substance of any structure.
It is especially remarkable that a prophylactic effect is produced when hexopyranose compounds of the formula I are administered from just a few days up to a few, for example four, weeks before Infection* and a therapeutic effect still occurs on administration several days, for example 1 week, after infection.
. Remarkable and hitherto unprecedented le also the broad viral spectrum against which the above-mentioned compounds are effective· The hexopyranose compounds of the formula I can be used especially for the prophylaxis and treatment of diseases caused by the viruses specified in detail hereinafter [for nomenclature cf. J.L. Melnick, Prog. med. Tirol. 26, 214-232 (I960) and 28, 208-221 (1982)]: DMA viruses with cubic symmetry and naked nucleocapsid, DMA viruses with enveloped virion and also RMA viruses with cubic, and those with helical, synmetry of the capsid.
Preferably, the compounds of the formula I are used in the case of DMA viruses with enveloped virion and cubic symmetry of the capsid, in the case of RMA viruses with cubic symmetry of the capsid and naked virion, and in the ease of RMA viruses with helical symmetry of the capsid, in which the nucleocapsid casing is located at the surface membrane, but also In the base of A&enovirldae, Poxvlridae and Corona30 viridae, such as, especially, human coronaviruses.
The compounds of the formula I are uaed especially in the case of Herpet ovir idae, Picoraavirldae and myxoviruses, but also in the case of mastadenoviruses, such as, especially, human adenoviruses, in the case of Chordopoxvirlnae, such as, chiefly, orthopoxviruses, such as, especially, for example, vaccinal viruses, in the case of Reoviridae, chiefly (especially human) rotaviruses, and also in the case of Caliciviridae and Rhabdovir idae, such as, especially, vesiculoviruses in humans as well as horses, cows and pigs.
The conpounds of the formula I are mainly used in the case of Alphaherpesvirinae like Varicellaviruses, * for example human varicellazoster viruses, rhinoviruses, cardioviruses and Orthanyxoviridae, but also in the case of Betaherpesvirinae, such as, especially, human * cytomegaloviruses, in the case of aphthoviruses, especially aphthoviruses of cloven-hoofed animals, such as, chiefly, cows, and in the case of Paramyxoviridae, such as, especially, pneumoviruses, for exanple respiratory syncytial viruses in humans, and such as, in . addition, morbilliviruaes or paramyxoviruses, such as parainfluenza viruses, for exanple human parainfluenza viruses, including Sendai viruses, as well as in the case of arboviruses or vesiculoviruses, for exanple vesicular stomatitis viruses.
Above all the conpounds of the formula I are used for sinplex viruses, for exanple human herpes sinplex viruses of types 1 and 2, and in the case of human encephalomyocarditis viruses, influenza viruses, such as mainly influenza A and influenza B viruses, and most especially in the case of the viruses mentioned in the Exanples.
The hexopyranose conpounds of the formula X can be used in accordance with the invention by administering than enterally or parenterally, especially to30 gether with suitable adjuncts or carriers. Preferably they are applied to the mucous membrane, for exanple intranasally, rectally, vaginally or to the conjunctiva of the eye, or orally. The antiviral effect occurs, however, also if administered in other ways, for exaiple subcutaneously, intravenously, intramuscularly or if applied to the skin. * 1 The dosage of the active ingredient depends, inter alia, on the species of the warm-blooded animal , the defensive condition of the organism, the mode of administration and the nature of the virus* There is no especially pronounced relationship between dosage and action.
For prophylaxis, a single dose of from approximately 0*01 mg to approximately 25 mg, preferably from 0.05 to 7 mg, for example 0*5 mg, of active ingredient is administered to a warm-blooded animal of approximately 70 kg body weight, for example a hua;n. The prophylactic effect of this dose lasts for several weeks. If required, tor example at times of increased risk of infection, the administration of this dose can be repeated.
The therapeutic dose for warm-blooded animals of approximately 70 kg body weight is between 0.1 mg and 50 mg, preferably between 1 and 10 mg, for example 5 mg, especially when administered orally* The dosage in the case of topical, especially intranasal, administration is lower by up to a factor of 10* If required, the administration of the hexopyranose compounds of the formula I oan be repeated until there is an Improvement in the disease. Normally, however, one administration is adequate* The hexopyranose compounds of the formula I are used in accordance with the invention in the form of pharmaceutical preparations that contain a pharmacologically active amount of the active ingredient together with pharmaceutically acceptable carriers that are suitable for enteral, for example oral, or parenteral, administration and may be inorganic or organic, solid or liquid* For example, tablets or gelatin capsules that contain the active ingredient together with diluente, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycerin, and/or lubricants, for example siliceous earth, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, are used. Tablets may likewise contain binders, for example magnesium aluminium silicate, starches, such , as corn, wheat or rice starch, gelatin, methyl cellulose, sodium carboxymethyl cellulose and/or polyvinylpyrrolidone and, if desired, disintegrators, a for example starches, agar, alginic acid or a salt lo thereof, such as sodium alginate, and/or effervescing mixtures, or adsorbents, colouring substances, flavouring substances and sweeteners· Furthermore, the pharmacologically active compounds of the present invention can be used in the form of parenterally administrable preparations, for example infusion solutions. Such solutions are preferably isotonic aqueous solutions or suspensions, and these, for example in the case of lyophilised preparations that · contain the active ingredient alone or together with a carrier, for example mannitol, can be prepared before use. The pharmaceutical preparations may be sterilised and/or contain adjuncts, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, saltsfbr regulating the osmotic pressure and/or buffers# The pharmaceutical preparations in question are produced in a manner known per se. for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes, and contain from approximately 0.001 % up to approxi30 mately 95 % of active ingredient, an active ingredient content of lees than 1 % being suitable especially for preparations that are to be topically administered· Pharmaceutical preparations for enteral or parenteral administration that contain an effective · amount, but less than 1% by weight, of a hexopyranose compound of the formula I or a salt thereof together with a pharmaceutical carrier, are novel and the invention relates also to these.
The invention relates especially to pharmaceutical . 5 preparations containing a hexopyranose compound of the formula X that is mentioned below as being preferred for the use in accordance with the invention· The following forms of administration, which have not been prior-published, of hexopyranose compounds IO of the formula X are especially suitable for the use in accordance with the invention: creams, ointments, pastes or a gel with an active ingredient content of from 0.001 % up to, but exclusive of, 1 % by weight, principally of from 0.001 % to 0.9 %, especially from 0.01 % to 0.1 %, for example 0.05 %, for example ointments for intranasal administration, vaginal or rectal suppositories or lipsticks, aqueous solutions having an active ingredient content of from 0.001 % by weight up to, but exclusive of, 1 % by weight, principally 2o from 0.001 % to 0.9 %, especially from 0.05 % to 0.5 %, for example 0.1 %, preferably isotonic, sterile and physiologically tolerable solutions, for example eye drops, preferably in disposable, micro-containers, or sprays for use in the mouth* or pharyngeal cavity, or tablets or capsules having an active ingredient content of from 0.1 up to, but exclusive of, 1 % by weight, for example 0.9 The pharmaceutical preparations described in the Examples are especially suitable.
Creams are oil-in-water emulsions that contain more than 50 % of water. There are used as oily base substances especially fatty alcohols, for example lauryl, cetyl or stearyl alcohol, fatty acids, for example palmitic or stearic acid, liquid to solid waxes, for example isopropyl myristate, wool wax or beeswax. and/or hydrocarbons, for example petroleum jelly (petrolatum) or paraffin oil· There come into consideration as emulsifiers surface-active substances having predominantly hydrophilic properties, such as corresponding non-ionic emulsifiers, for example fatty acid esters of polyalcohols or ethylene oxide adducts thereof, such as polyglycerin fatty acid esters or polyoxyethylene sorbitan fatty acid esters (Tweens^ , also polyoxyethylene fatty alcohol ethers or fatty acid esters, or corresponding ionic emulsifiers, such as alkali metal salts of fatty alcohol sulphates, for example eodium lauryl sulphate, eodium cetyl sulphate or sodium stearyl sulphate, which are usually used in the presence of fatty alcohols, for example cetyl alcohol or stearyl alcohol· Additives to the aqueous phase are, inter alia· agents that reduce the drying out of creams, for example polyalcohols, such as glycerin, sorbitol, propylene glycol and/or polyethylene glycols, and also preservatives and perfumes.
Ointments are water-in-oil emulsions that contain up to 70 %, preferably from approximately 20 % to approximately 50 ¢, of water or aqueous phase· There come into consideration as fatty phase especially hydrocarbons, for example petroleum jelly, paraffin oil and/or hard paraffine, which, in order to improve the water-binding ability, preferably contain suitable hydroxy compounds, such as fatty alcohols or esters thereof, for example cetyl alcohol or wool wax alcohols, or vool wax. Emulsifiers are corresponding lipophilic substances, such as sorbitan fatty acid esters (Spans), for example sorbitan oleate and/or sorbitan isostearate· Additives to the aqueous phase are, for example, humectants, such as polyalcohols, for example glycerin, propylene glycol, sorbitol and/or polyethylene glycol, as well as preservatives and perfumes.
Fatty ointments are anhydrous and contain as the base substance especially hydrocarbons, for example paraffin, petroleum jelly and/or liquid paraffins, also natural or partially synthetic fats, for example coconut fatty acid triglyceride, or preferably hardened oils, for example hydrogenated peanut or castor oil, and fatty acid partial esters of glycerin, for example glycerin mono- and di-stearate, as well as, for example, the fatty alcohols that increase water-ab1O sorbing ability, emulsifiers and/or additives mentioned in connection with the ointments.
Bastes are creams and ointments with secretionabsorbing powder constituents» such as metal oxides, for example titanium oxide or zinc oxide, and also talc and/or aluminium silicates, the purpose of which is to bind any moisture or secretions present.
Foams are administered from pressurised containers and are liquid oil-in-water emulsions in aerosol form, halogenated hydrocarbons, such as chlorofluoro20 lower alkanes, for example dichlorddifluoromethane and dichlorotetrafluoroethane, being used as propellants. There are used as oily phase, inter alia, hydrocarbons, for example paraffin oil, fatty alcohols, for example cetyl alcohol, fatty acid esters, for example isopro25 pyl myristate, and/or other waxes. There are used as emulsifiers, inter alia, mixtures of those having predominantly hydrophilic properties, such as polyoxyethylene sorbitan fatty acid esters (Tweens (Trade Hark]), and those having predominantly lipophilic pro30 perties, such as sorbitan fatty acid esters (Spans [Trade Hark]). In addition there are the customary additives» such as preservatives.
Tinctures and solutions usually have an aqueous/ ethanolic base substance to which there are added, later alia, polyalcohols, for example glycerin, gly16 cols and/or polyethylene glycol, as humectants for reducing evaporation, and fat-restoring substances, such as fatty acid eeters vlth low polyethylene glycols, that is to say lipophilic substances soluble in aqueous mixture as a replacement for the fatty substances removed from the skin by the ethanol, and, if necessary, other adjuncts and additives.
The manufacture of the topically administrable pharmaceutical preparations is carried out in a manner io known per se. for example by dissolving or suspending the active ingredient in the base substance, or in a portion thereof, if necessary. When processing the active ingredient in the form of a solution, it is usually dissolved in one of the two phases before emul15 sification; when processing in the form of a suspension it is mixed with a portion of the base substance after emulsification and then added to the remainder of the formulation.
The above terms used for the definition of the compounds of the formula I have, within the scope of this application, preferably the following meanings: Acyl, for example as r\ R^, and is especially the acyl radical of an organic carboxylic acid, especially an aliphatic, but also a cycloali25 phatic, cycloaliphatic-aliphatic, aromatic or araliphatic carboxylic acid, which may have, for example, up to 90 carbon atoms.
Aliphatic carboxylic acids are, inter alia, alkanecarboxylio acids that are unsubstituted or sub30 stituted, for example, by hydroxy or etherifled or esterified hydroxy, such as lower alkoxy or lower alkanoyloxy, or by unsubstituted or substituted amino, such as lower alkylamino, di-lower alkylamino or acylamino, for example alkanoylamino, and corresponding alkene- or alkyne-carboxylic acids that may have one or more double or triple bonds. These acids may contain, 7 ο for example, up to 90 carbon atoms, R as the radical of an dliphatic carboxylic acid, in the case when X1 represents a group of the formula preferably representing the acyl radical of an unsubstituted or hydroxy-substituted lower alkanecarboxylic acid.
Cycloaliphatic carboxylic acids may be monocyclic or polycyclic and as a cycloaliphatic radical contain monocyclic or polycyclic cycloalkyl that is unsubstituted or is substituted, for example by hydroxy, and corresponding cyoloalkenyl.
In cycloaliphatic-aliphatic radicals, the cycloaliphatic moiety and the aliphatic moiety have the meanings given above; such radicals are especially monocyclic or polycyclic cycloalkyl-lower alkyl* Aromatic and araliphatic carboxylic acids are, inter alia* benzoic or phenyl-lower alkanecarboxylic acids that are unsubstituted or substituted, for example by lower alkyl, hydroxy, lower alkoxy or halogen* Aliphatically substituted silyl is e.g. tri-lower alkylsilyl.
Substituents of alkylene, which Is represented by the radicals Υ1, Y2 and y\ are, inter alia, hydroxy, esterified or etherified hydroxy, such as acyloxy, for example lower alkanoyloxy, or lower alkoxy, amino or substituted amino, such as lower alkylamino, di-lower alkylamino or acylamino, for example lower alkanoylamino· In an alkylene radical that is interrupted by iminocarbonyl or oxycarbonyl, there may be one or more, for example two, such groups and these may be present as groups of the formula -N(R^)-C(=O)- or -0-0(=0)-, and as groups of the formula -0(=0)-^(^1^). or -0(=0)-0-, and R^ has the meaning given above and preferably represents hydrogen. An alkylene radical formed by the groups R^ and R® and having 3 or 4 carbon atoms in the chain may be substituted, for example by hydroxy, which may be acylated, for example by a group of the formula Ia· Δη aliphatic radical having at least 7 carbon · atoms that is the group R1^ or etherlfies a hydroxy yg 17 group in a radical R or R is especially a corresponding unsubstituted or substituted alkyl radical « but may also represent a corresponding unsaturated io radical, such as an unsubstituted or substituted alkenyl radical having one or more double bonds, such radicals having, for example, from 7 up to and including 90 carbon atoms, preferably from 7 up to and including 30 carbon atoms· Substituents of such aliphatic radicals are, for example, hydroxy, etherified or esterified hydroxy, such as lower alkoxy or lower alkanoyloxy and/or unsubstituted or substituted amino, such as lower alkylamino, di-lower alkylamino or alkanoylamino· Δ corresponding cycloaliphatic radical that is the group R1^ or a radical etherifying a hydroxy group 16 17 in a radical R or R is especially monocyclic or polycyclic cycloalkyl, or also corresponding cycloalkenyl, which may contain one or more double bonds· Such radicals contain at least 7> and preferably from to 30, carbon atoms, and may, in addition, bs substituted, for example by hydroxy, etherified or esterified hydroxy, such as lower alkoxy or lower alkanoyloxy, or by unsubstituted or substituted amino, such as lower alkylamino, di-lower alkylamino or alkanoylamino.
Etherified hydroxy or substituted amino as a radical R^ or Ru is, for example, lower alkoxy, or, for example, lower alkylamino, in which lower alkyl may be substituted. · Δ radical esterifying a hydroxy group in a radical y g 17 R or R is especially an acyl radical of an organic carboxylic acid, especially of one of the above-mentioned aliphatic and cycloaliphatic, cycloaliphaticaliphatic, aromatic or araliphatic, carboxylic acids, preferably having from 7 to 90 carbon atoms· Etherified hydroxy or mercapto or esterified hydroxy or mercapto other than a radical of the formula Id as substituent of lower alkyl Εθ is, for example, lower alkoxy, acyloxy, such as alkanoyloxy, wherein, alkanoyl contains up to 90, for example from 7 to 30, carbon atoms and may optionally be substituted, for example by hydroxy, or is halogen, lover alkylthio or acyl thio, such as alkanoyl thio, wherein alkanoyl contains up to 90, for example from 7 to 30, carbon atoms· Substituted amino other than a radical of the formula • g Id as substituent of a lower alkyl group H is, for example,, lower alkylamino, guanylamino or acylamino, such as alkanoylamino, wherein alkanoyl may contain up to 90, for example up to 30, carbon atoms· Esterified carboxy as substituent of a lower alkyl radical Εθ is preferably carboxy esterified by an aliphatic radical, such as alkyl having up to 30 carbon atoms, that is to say, for example, corresponding alkoxycarbonyl, whilst corresponding amidated carboxy, is, for example, aminocarbonyl or lower alkylaminocarbonyl, wherein lower alkyl may be substituted, for example by carboxy, alkoxyearbonyl or aminocarbonyl· Esterified or amidated carboxy in a radical Εθ may also be a radical of the formula O -C E—( Y2 X4 )m A2 (Ida) m especially phenyl that is unsubstituted or substituted, for example by lower alkyl, hydroxy or etherifled or esterified hydroxy, such as lower alkoxy, or halogen, whilst nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring as corresponding substituent of Is monocyclic or bicyclic heteroaryl containing one or two nitrogen atoms as ring members· Etherifled mercapto as radical or is es< pecially lower alkylthio, whilst in a lower alkylamino stituted, for example by carboxy, lower alkoxycarbonyl or aminocarbonyl· * or N-lower alkylcarbamoyl, wherein lower alkyl may be substituted, for example by carboxy, lower alkoxycarbonyl or aminocarbonyl.
In the context of the present description, the general terse used above have the following meanings, radicals and compounds that are termed lower* containing up to and Including 7, preferably up to and including 4, carbon atoms: Alkyl is, for example, lower alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tributyl* sec.-butyl or tert.-butyl, also n-pentyl, neopentyl, n-hexyl or n-heptyl, or higher alkyl* such as straightchain or branched octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, nonadecyl or heneicosyl, and also higher alkyl of the triacontyl, tetracontyl, pentacontyl, hexacontyl, heptacontyl, octacontyl or nonacontyl series.
Lower alkoxy is, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert·butoxy.
Alkanoyloxy Is lover or higher alkanoyloxy, lower alkanoyloxy being, for example, formyloxy, acetoxy, propionyloxy or butyryloxy, whilst higher alkanoyloxy is, • 5 for example, lauroyloxy, myristinoyloxy, palmitoyloxy, stearoyloxy or behenoyloxy· Alkanoyloxy substituted by hydroxy, for example higher alkanoyloxy, is, inter • alia* mycoloyloxy.
Lower alkylamino is, for example, methylamino, lo ethylamino, n-propylamino or isopropylamino. Di-lower alkylamino is, for example, dimethylamino, dlethylamino or di-isopropylamino· Alkanoylamino is lower alkanoylamino, for example formylamino, acetylamino or proplonylamino, or higher alkanoylamino, for example lauroylamino, palmitoylamino, stearoylamino or behenoylamino.
An alkanecarboxylic acid is, for example, a lower alkanecarboxylic acid, such as acetic acid, propionic acid, butyric acid or oaprolc acid, or a higher alkane20 carboxylic acid, such as lauric acid, myrlstic acid, palmitift acid, stearic acid or behenic acid, whilst, for example, an alkanoic acid substituted by hydroxy may be, inter alia, mycollc acid· Alkene* and alkyne-carboxylic acids are, inter alia» lower alkene- and lower alkyne-carboxylic acids, such as acrylic acid, crotonic acid or tetrollc acid, or higher alkene- and higher alkyne-carboxylic acids, such as undecylenlc acid, oleic acid or elaidic acid· The acyl radical of a lower alkanecarboxylic acid, which is the group It in the c&ae when X represents the radical of the formula -N(R^)-, is especially acetyl or hydroxyacetyl, and propionyl· Cycloalkyl is, for example, cyclopentyl, cyclo• hexyl or adamant yl, whilst cycloalkenyl may be, for example, 1-cyclohexenyl, and cycloalkyl-lower alkyl may be, for example, 3-cholanylmethyl or the acyl radical of cholanio acid· Phenyl-lower alkanecarboxylic acids are, for example, phenylacetic acid or phenylpropionic acid, which may be substituted, for example as stated. « Halogen is preferably halogen having an atomic number of up to 35 and represents especially chlorine, but also fluorine or bromine· « Tri-lower alkylsilyl is especially trimethylsllyl· Alkylene is straight-chain or branched and is especially lower alkylene, for example methylene, ethylene, 1,2-propylene, 1,3-propylene or 1,6-hexylene, but also higher alkylene, such as 1,11-undecylene.
Alkenyl is lower alkenyl, for example allyl or methallyl, or higher alkenyl, for example decenyl.
Lower alkylthio is, for example, methylthio or ethylthio.
In an alkanoyl thio radical, the alkanoyl radical represents lower alkanoyl, for example acetyl, propionyl, butyryl or hexanoyl, but may also represent higher alkanoyl, for example lauroyl, myristinoyl, palmitoyl, stearoyl or behenoyl· Alkoxycarbonyl is lower alkoxycarbonyl, for example methoxycarbonyl, ethoxycarbonyl or tert.-butoxycarbonyl, or higher alkoxycarbonyl, for example dodecyloxy carbonyl, tetradecyloxycarbonyl, hexadecyloxycarbonyl or henelcosyloxycarbonyl· Lower alkylaminocarbonyl is, for example, methylaminocarbonyl or ethylaminocarbonyl, also carboxy-, lower alkoxycarbonyl- or carbamoyl-lower alkylaminocarbonyl, such as carboxyme thylamino carbonyl, 1-oarboxyethylaminocarbonyl, methoxycarbonylmethylaminocarbonyl or carbamoylmethylaminocarboziyl· Nitrogen-containing heteroaryl having 5 or 6 ring . · members in the heterocyclic ring is, for example, imidazolyl, such as 4-imidazoiyl, or indolyl, such aa 3-indolyl.
The hexopyranose compounds of the formula 1 may be in the form of isomeric mixtures or pure isomers.
The optionally substituted 1-hydroxy group of the formula -0-R^ may have the a- or the β-οοηflguration; the novel compounds of the formula I may, however, also be in the form of a mixture of the l-«and Ι-β-lsomers. in the compounds of the formula 1, the proton bonded to phosphorus via an oxygen atom can readily be replaced by a cation, that is to say, the compounds form salts. In this case, the compounds of the formula 1 may be ln salt form or in the form of a mixture of il 4 the free compounds and their salts. These are especially metal or ammonium salts, such as alkali metal and alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, and ammonium salts, or salts with suitable organic amines, such as lower alkylamines, for example triethylamine. Compounds of the formula I having basic groupe, for example amino groups, are in the form of internal salts but, when there are more basic than acidic groups in a molecule XO of the formula 1, they may also form acid addition salts with external acids, such as salts with inorganic acids, such as mineral acids, for example hydrochloric, sulphuric or phosphoric acid, or organic carboxylic or sulphonic acids, for example acetic, maleic, fumaric, tartaric, citric, methanesulphonic or 4-toluenesulphonic acid. Only the pharmaceutically acceptable, non-toxic salts are used therapeutically.
The present invention relates especially to the use of: (a) compounds of the formula X in which X3, and X3 have the meanings given above, R^ represents a radical of the formula la in which η, Ζ1, Υ1, X3 and A1 have the meanings given above, each of R3, R3,3 and R3*3, independent25 ly of one another, represents hydrogen, acyl other than a radical, of the formula Ia in which n represents 1, or aliphatically substituted silyl, R3, R4, r\ r\ R® and R^° have the meanings given above, R® represents hydrogen or lower alkyl that is unsubstituted or substituted by free or etherified hydroxy or mercapto, by esterified hydroxy or mercapto other than a corresponding group of the formula Id or by free amino or substituted amino other than a corresponding group of the formula Id, by free, io esterified or amidated carboxy, by cycloalkyl, by carbocyclic aryl or by nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring, or and Εθ together represent unaubstituted or substituted 1,3- or 1,4-lower alkylene, and in which each q IT. of R and fi , independently of the other, represents free hydroxy or mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or substituted amino other than a radical of the formula Ie, it being possible for free functional groups to be in protected form, and of pharmaceutically acceptable salts of such compounds; (b) compounds of the formula I in which Xx and X have the meanings given above, E represents a radical of the formula Ia in which £, z\ I3*, X^ and A1 have the meanings given above, each of e\ R3·2 and independently of one another, represents hydrogen, acyl other than a radical of the formula Ia in which n represents 1, or aliphatically substituted silyl, 4 5 7 8 XO R , R , R , R , R and R have the meanings given above, R6 represents hydrogen or lower alkyl that is unsubstituted or substituted by free or etherified hydroxy or mercapto, by esterified hydroxy or mercapto other than a corresponding group of the formula Id, by free amino or substituted amino other than a corresponding group of the formula Id, by free, esterified or amidated carboxy, by cycloalkyl, 2β by carbocycllc aryl or hy nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring, or S? and R® together represent unsubstituted or substituted 1,3- or 1,4-lower alkylene, and in which q m . each of R and R , independently of the other, represents free hydroxy or mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or substituted amino other than a radical of the formula Ie, it being possible for free functional groups to be in protected form, and of pharmaceutically acceptable salts of such compounds; (c) compounds of the formula I in which X1 and X2 have the meanings given above, R^ represents a radical of the formula Ia in which £, Ζ1, I1, !? and A1 have the meanings given above, each of r\ R2 and R12, independently of one another, represents hydrogen, acyl other than a radical of the formula Ia in which £ represents 1, or aliphatically substituted silyl R8 and R10 R3, R4 have the meanings given above, R® represents hydrogen or lower alkyl that is unsubstituted or substituted by free or etherified hydroxy or mercapto, by esterified hydroxy or mercapto other than a corresponding group of the formula Id, by free amino or substituted amino other than a corresponding group of the formula Id, by free, esterified or amidated carboxy, by cycloalkyl, by carbocycllc aryl or by nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring, or R^ and R® together represent unsubstituted or substituted lower alkylene having 3 or 4 carbon atoms in the chain, and in which each of R7 and R , independently of the other, represents free hydroxy or mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or substituted amino other than a radical of the formula £e, it being possible for free functional groupe to be in protected form, and of pharmaceutically acceptable salts of such compounds; or (d) conpounds of the formula I in which X1 and X2 have the meanings given above, each of R1, R2, R12 and R13, independently of one another, represents hydrogen, acyl other than a radical of the formula la in which n repre3 *" 4 5 sents 1, or aliphatically substituted silyl, R , R , R , R7, R8 and R10 have the meanings given above, R8 represents lower alkyl substituted by a radical of the formula Id, in *9 9 A O which m, Ε, Ζ , Y , X and A have the meanings given above, or R8 represents lower alkyl substituted by a group of the formula Ida in which m, Ε, Y2, x^ and A2 have the mean*** 9 11 ings given above, and in which each of R and R , independently of the other, represents free hydroxy or mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or substituted amino other than a radical of the formula Ie, 2o it being possible for free functional groups to be in protected form, and of pharmaceutically acceptable salts of such compounds, and to novel pharmaceutical pre-, parationa containing these conpounds.
The invention includes especially the use of D-galac25 to-, D-manno- or particularly D-glucopyranose 2 compounds of the formula I, in which X and X have 2 12 13 the meanings given above, each of R , R , R and R , independently of one another, represents hydrogen, the acyl radical of an aliphatic, cycloaliphatic, aromatic or ataliphatic carboxylic acid, especially of an alkanecarboxylic acid having up to 90 carbon atoms, that is unsubstituted or substituted, for exanple by hydroxy, amino and/or alkanoylamino, such as higher alkanoylamino, a tri-lower alkylsilyl group or a I radical of the formula la in which £ and X^ have the meanings given above, Z1 represents thiocarbonyl or, preferably, carbonyl, represents lower alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, and A1 represents a radical of the formula lb 1*5 or Ic, ln which Br represents an aliphatic, radical having at least 7 carbon atoms, R1® represents hydrogen and a17 represents 2-hydroxyethyl or 1,2-dihydroxyethyl, in which at least one hydroxy group is etherifled by an aliphatic radical having at least 7 and up to 90 carbon atoms or is esterified by a corresponding yg n j aliphatic acyl radical, or each of R and R , independently of the other, represents hydroxymethyl etherifled by an aliphatic radical having at least 7 ' and up to 90 carbon atoms or esterified by a corresponding aliphatic acyl radical, R^, R4, R? and R8 have the meanings given above, R^ represents hydrogen or lower alkyl which is unsubstituted or substituted by a radical of the formula Id ln which £, B and X4 2 have the meanings given above, Z represents thio-, carbonyl or, especially, carbonyl, I2 represents lower alkylene which may be interrupted by iainocarbonyl or oxycarbonyl, and A^ represents a radical of the formula lb or Ic in which R1^ represents an aliphatic radical having at least 7. carbon atoms, a16 represents hydrogen and R1? represents 2-hydroxyethyl or 1,2i dihydroxy ethyl, in which at least one hydroxy group —is esterified by an aliphatic radical having at least and up to 90 carbon, atoms or by a corresponding ali16 17 phasic acyl radical, or each of R and R , independently of the other, represents hydroxymethyl etherified by an aliphatic radical having at least 7 and up to 90 carbon atoms or esterified by a corresponding . aliphatic acyl radical, or R^ represents lower alkyl substituted by hydroxy or mercapto, by hydroxy or mercapto etherified by an aliphatic radical containing up to 90 carbon atoms, by hydroxy or mercapto that ia esterified by an aliphatic acyl radical containing up to 90 carbon atoms and is other than the group of the formula Id, by amino, by amino that is substituted by an acyl radical containing up to 90 carbon atoms and is other than a radical of the formula Id, by free carboxy, by lower alkoxycarbonyl, by carbamoyl, by lower alkylaminocarbonyl, by carboxy-lower alkylaminocarbonyl or by amidated carboxyl of the formula Ida, by phenyl that is unaubstituted or substituted by hydroxy, lower alkoxy or halogen, or'by imidazolyl or indolyl, or and r together represent 1,3- or 1,4-lower q τι alkylene, each of R and R , independently of the other, represents hydroxy, lower alkoxy, amino, lower alkylamino, carboxy-lower alkylamino, or a radical of the formula Ie, in which J? and have the meanings •i given above, Y represents lower alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, and represents a radical of the formula lb or Ic, In which R^5 represents an aliphatic radical having at least 7 carbon atoms, R represents hydrogen and R ' represents 2-hydroxyethyl or 1,2-dihydroxyethyl, in which at least one hydroxy group is etherified by an aliphatic radical having at least 7 and up to 90 carbon atoms or is esterified by a corresponding aliphatic acyl radical, or each of H16 and R1?, independently of the other, represents hydroxymethyl etherified by an aliphatic radical having at least 7 and up to 90 carbon atoms or esterified by a corresponding aliphatic acyl radical, and represents hydrogen, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylaminocarbonyl or carboxy-lower alkylaminooarbonyl, it being possible for free functional groups to be in protected form, with the proviso that the compounds of the formula I have at least one radical A1, A2 or A5, and of pharmaceutically acceptable salts of such compounds, and to novel pharmaceutical preparations containing these compounds.
The invention relates especially to (e) the use of the D-galacto-, D-manno- or especially D-glucopyranose compounds of the formula I mentioned under (a), (b), (c) and (d) in which one, several or all of the * radicals X^ X2, R1, R2, R5, R4, R5, R6, R7, R8, R9, rIO, Β?-3·, R12 and R^ have the meanings given in the preceding paragraphs, and of pharmaceutically acceptable salts of such compounds· The invention relates more especially to (f) the use of D-glucopyranose compounds of the formula If r13-O. a CH, l/' R12-l· R^-CH 3 \ ,/ 1 la c—κ—c—CII h *7 H O R O ft >O-Rt O«C-R, I a -N—CH—CH. H (If) H ii •CH2-C-R^ in which R. represents hydrogen, lower alkanoyl or a a 1 group of the formula Ia in which £ represents 1, Z represents carbonyl, T1 represents lower alkylene which may he interrupted hy iminocarbonyl, X^ represents a group of the formula -0- or -39H-, and A^ represents a radical of the formula Ih or Xc, in which R ' represents an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted hy hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, R16 17 represents hydrogen and R ' represents 2-hydroxyethyl or 1,2-dihydroxyethyl, the hydroxy groups in a radical R3*? being etherified by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 lo carbon atoms or being esterified hy an alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or each of R and R independently of the other, represents hydroxymethyl in which the hydroxy group is etherified by an alkyl radical having from 7 to 30 carbon atoms that is unaubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms or is esterified by an al kanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, represents lower alkanoyl, hydroxylower alkanoyl, benzoyl or a group of the formula Ia, in which £, Ζ3*, T3*, X^ and A3' have the meanings given above, R£ represents hydrogen or lower alkanoyl, represents hydrogen, alkanoyl or hydroxyalkanoyl having up to 90 carbon atoms, alkanoylaminoalkanoyl having up to 30 carbon atoms or a group of the formula Ia In which £, Z3*, T3', X^ and A3* have the meanings given above, and R? represent hydrogen or methyl, Βθ represents hydrogen or lower alkyl that is unsubstituted or substituted by free hydroxy or mercapto, lower alkoxy, lower alkylthio, alkanoyloxy or hydroxyalkanoyloxy having up to 90 carbon atoms, phenyl, imidazo35 lyl, indolyl or hy a group of the formula Id, in which £ represents 1, E represents a group of the formula 2 2 -0- or -3-, Z represents carbonyl, Y represents lover alkylene which may be interrupted by iminocarbonyl, X4 represents a group of the formula -0-, and A2 represents a radical of the formula lb or Ic, in which R1^ represents an alkyl radical having from 7 to 30 carbon Λ atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, 17 R represents hydrogen and & represents 2-hydroxy- * ethyl or 1,2-dihydroxyethyl, the hydroxy groups in a radical R ' being etherified by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms or being esterified by an alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or 16 17 each of R and R , independently of the other, represents hydroxymethyl In which the hydroxy group is etherified by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterified by an alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, and each of the radicals Q 11 fi^ and R^ , independently of the other, represents hydroxy, lower alkoxy, amino, lover alkylamino, carboxy-lower alkylamino or a radical of the formula Ie R in which X-* represents a group of the formula -0- or -MH-, Y5 represents lower alkylene which may be interrupted by iminocarbonyl, X® represents a group of the formula -0-, and A~ represents a radical of the IB formulalb or Ic, in which R represents an alkyl radical having from 7 to 30 carbon atoms that is un- * substituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, R3*® represents hydrogen and R represents 2-hydroxyethyl or 1,2-dihydroxyethyl, the hydroxy groupe in a radical R^? being etherifled by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or being esterified by an alkanoyl radical having from 7 to 90 carbon atoms that is unsubs tituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or each of 10 and R3·?, independently of the other, represents hydroxymethyl in which the hydroxy group is etherifled by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterified by an alkanoyl radical having from 7 to carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 q carbon atoms, Rf preferably represents one of the amino ii a groups and R^ preferably represents hydroxy, with the proviso that the compounds have at least one, and preferably only one, radical A , A or Ay, and of pharmaceutically acceptable salts thereof, and to novel pharmaceutical preparations containing these compounds.
The invention relates especially to (g) the use of the D-glucopyranose compounds of the formula 1 mentioned under (a), (b), (c) and (d) in which X1 represents a 2 group of the formula -NH-, X represents a group of the formula -0-, R4, R^, R® and R1® represent hydrogen, and R1, R2, R3, R6, R7, R9, R11, R12 and R13 have the meanings given in the foregoing section for the radicals Rj, R2, H3, R®, R7, R9, rJ1, rJ2 and h£3, respectively, and of pharmaceutically acceptable salts thereof· The invention relates chiefly to h) the use of compounds of the formula 1 in which X1 represents a group of the formula -H(R^)-, R1^ representing hydrogen or O^-alkyl, X represents oxygen, It represents hydrogen, lower alkanoyl, or a group of the formula la in which a represents 0 or 1, 21 represents carbonyl, 7^ represents lower alkylene which may be interrupted by iminocarbonyl, X^ represents oxygen and A3* represents 15 a radical of the formula lb or le in which R represents an alkyl or alkenyl radical having from 7 to 30 carbon atoms that Is unsubstituted or substituted by io hydroxy, amino and/or alkanoylamino having up to 22 17 carbon atoms, R represents hydrogen and R represents 2-hydroxyethyl or 1,2-dihydroxyethyl, at least one hydroxy group in a radical R being etherified by an alkyl or alkenyl radical having from 7 to 30 carbon J 5 atoms, or being esterified by an alkanoyl or alkenoyl radical having from 7 to 30 carbon atoms, or each of R and R ', independently of the other, represents hydroxymethyl in which the hydroxy group is etherified by an alkyl or alkenyl radical having from 7 to 30 2o carbon atoms, or is esterified by an alkanoyl or o alkenoyl radical having from 7 to 30 carbon atoms, R represents lower alkanoyl, hydroxy-lower alkanoyl, benzoyl or, independently of r\ R^2 and R1^, a group of the formula Ia as defined hereinbefore, each of r\ r\ R^, R? and R®, independently of one another, represents hydrogen, methyl or ethyl, R^ represents hydrogen, or lower alkyl that is unsubstituted or substituted by free hydroxy, free mercapto, lower alkoxy, lower alkylthio, alkanoyloxy having from 2 to 30 carbon atoms, alkenoyl oxy having from 6 to 30 carbon atoms, phenyl, 4-hydroxyphenyl, or by a group of the formula Id in which m represents 0 or 1, E represents oxygen or sulphur, 22 represents carbonyl, 72 represents lower alkylene that is unsubstituted or substituted by phenyl and may be interrupted by iminocarbonyl, X^ represents 13 oxygen and A , independently of A and A , represents a radical of the formula lb or Ic as defined hereino 11 before in this Specification, each of fr and R , independently of the other, represents hydroxy, lower alkoxy, amino, lower alkylamino, carboxy-lower alkylamino, lower alkoxycarbonyl-lower alkylamino, carbamoyl-lower alkylamino, or a radical of . the formula Ie in which X^ represents oxygen or RH, Y^ represents lower alkylene which may be interrupted by iminocarbong 3 1 lo yl, % represents oxygen and A-\ independently of Δ and A, represents a radical of the formula lb or Ic as defined hereinbefore in this Specification, R10 represents hydrogen, R represents hydrogen, lower alkanoyl or the same radical as R^\ and R1^ represents hydrogen, or alkanoyl or alkenoyl each having up to 30 carbon 2 atoms or, independently of R and R , a radical of the formula la as defined hereinbefore in this-Specif ication, with the proviso that the compounds contain at least one, and at most two, radicals selected from 12 3 the group A , A and A·7, and the use of pharmaceutically acceptable salts of these compounds· The invention relates especially to 1) the use of compounds of the formula I in which X1, represents the 2 1 group RH, X represents oxygen, R represents hydrogen 2 or lower alkanoyl, R represents lower alkanoyl, benzoyl or a group of the formula la in which £ represents 0 or 1, represents carbonyl, Y^ represents lower alkylene whioh may be interrupted by one or two iminocarbonyl groups, X^ represents oxygen, and A1 3o represents a radical of the formula lb or Ic in which R y represents an alkyl radical having from 7 to 22 16 1 7 carbon atoms, R represents hydrogen, and R ' represents 1,2-dihydroxyethyl in which each of the hydroxy groupe, independently of the other, is esterified by an alkanoyl or alkenoyl radical having from 10 to 22 carbon atoms, R^ represents hydrogen or methyl, R4, R , R' and R each represents hydrogen, R represents hydrogen, or lower alkyl that is unsubstituted or substituted by free hydroxy, alkanoyloxy having from to 22 carbon atoms, alkenoyloxy having from 6 to 22 . carbon atoms, phenyl or by a group of the formula Id in which £ represents 0 or 1, £ represents oxygen, Z 2 represents carbonyl, 7 represents lower alkylene that « is unsubstituted or substituted by phenyl and may be interrupted by iminocarbonyl, X4 represents oxygen and 1 5 A , independently of A and kr, represents a radical of the above-defined formula lb or Ic, each of R^ and R^3*, independently of the other, represents hydroxy, lower alkoxy, amino, lower alkylamino, e-carboxy-lower alkylamino*, α-lower alkoxycarbonyl-lower alkylamino, «-carbamoyl-lower alkylamino, or a radical of the formula Ie in which X^ represents the group NH, 7^ represents lower alkylene which may be interrupted by one or two iminocarbonyl groups, X^ represents oxygen *5 12 and k't independently of k and A , represents a radical of the formula lb or Ic defined hereinbefore, R3*8 τ ? represents hydrogen, R represents hydrogen, lower 1*3 13 alkanoyl or the same radical aa R , and R ' represents hydrogen, alkanoyl having from 2 to 22 carbon atoms, alkenoyl having from 6 to 22 carbon atoms or, indepen2 dently of R , a radical of the formula la as defined hereinbefore, and the use of pharmaceutically acceptable salts of these compounds.
The invention relates most especially to j) the use of compounds of the formula I in which I?- repre2 1 sente the group NH, X represents oxygen, R represents 2 hydrogen or C2_^-alkanoyl, R represents C^-alkanoyl or a group of the formula Ia in which £ represents 0 or 1, Z1 represents carbonyl, T1 represents lower alkylene which may be interrupted by one or tvo iminocarbonyl 1· groups, Hr represente oxygen, and A represents a 1C radical of the formula Xb or lc in which R represents an unbranched alkyl radical having from 12 to 18 carbon atoms, a16 represents hydrogen and R^7 represents 1,25 dipalmitoyloxyethyl or 2-oleoyloxy-l-palmitoyloxyethyl, R3 represents hydrogen or methyl, R , R’, R8 and each represents hydrogen, R® represents methyl, ethyl or isopropyl, each of which is unsubstituted or substituted by a radical of the formula Id IO in which m represents 0 or 1, £ represents oxygen, Z represents carbonyl, Y2 represents lower alkylene that is unsubstituted or substituted by phenyl and may be interrupted by one or two iminocarbonyl groups, X4 13 represents oxygen and A , independently of A and A^, represents a radical of the formula Ib or lc defined q ll hereinbefore, R represents amino, R represents c hydroxy or a radical of the formula Ie in which X 3 represents the group RH, Y-' represents lower alkylene which may be interrupted by one or two iminocarbonyl groups, X® represente oxygen and a\ independently of 1 2 A and A , represents a radical of the formula Ib or 12 Ic defined hereinbefore, R represents hydrogen, 13 acetyl or the same radical as R , and R represents 2 hydrogen, acetyl or, independently of R , a radical of the formula Ia as defined hereinhefore, and the use of pharmaceutically acceptable salts of these compounds.
The invention relates principally to k) the use of the above-mentioned compounds of the formula I in 12 3 which the radicals A , A and A , if present, represent radical of the formula Ic, and the use of pharmaceutically acceptable salts thereof.
The Invention relates especially to l) the use of the above-mentioned compounds of the formula I that carry only one phorphoryl substituent, that is in the 11 9 radical R or R , and the use of pharmaceutically acceptable salts thereof.
The Invention relates most especially to m) the use of the compounds of the formula 1 mentioned above under i) or k) that contain as the sugar moiety a derivative of D-glucose and that, in the case of asymmetric substitution, have at the C-R^ the (p)-configuration, at the C-Κθ the (L)-configuration, and at the C-N-Ηθ the (D)-configuration, and that carry (only) one phorphoryl substituent, that is in the radical R7 or R » wherein, in this phorphoryl substituent of the formula le, the radical A7 represents a radical of the formula lc, which is defined according to h) or j), and the use of pharmaceutically acceptable salts thereof.
The invention relates preferably to the use of compounds of the formula 1 that have at an asymmetrically substituted C(-H^)-atom the (D)-configuration, at an asymmetrically substituted C(-R^)-atom the (L)-confi figuration, and at the C(-N-R )-atom the (D) -configuration, and in which the sugar moiety is derived from (D)-glucose, Xx represents the group NH, X* represents oxygen, Η1, Β4, Β5, Β7, Β8, Β10, B12 and B13 each ό represents hydrogen, R represents Cn --alkyl or phenyl, R -represents hydrogen or C^-alkyl, R represents hydrogen, C^^-alkyl optionally substituted by hydroxy, methoxy, mercapto, methylmercapto or by halogen, phenyl or phenylmethyl each optionally substituted by hydroxy, methoxy or halogen, or heterocyclyl or heterocyclylmethyl each containing one or two aza atoms and having ring members, or R^ and Ηθ together represent triq methylene, one of the radicals R7 and Rx represents a radical of the formula Ie in which X^ represents the group NH or oxygen, represents C2_^-alkylene or a radical of the formula -u2-coo-U3 or H 3 -U-C-NH-U 3 9 *4 In which each of U. and U , independently of the other, represents C^^-alkylene that is unaubstituted or substituted by C^^-alkyl optionally substituted by hydroxy, lower alkoxy, mercapto or by lower alkylmer5 capto, or by phenyl or phenyl-lower alkyl each of which is optionally substituted by hydroxy, methoxy or halogen, or by heterocyclyl or heterocyclyl-(Clej-alkyl) each containing one or two aza atoms and having 5 or 6 ring members, X represents oxygen, and br represents a radical of the formula Ic in which R1^ represents hydrogen and R ' represents a 1,2-dihydroxyethyl or 2-hydroxyethyl group in each of which at least one of the hydroxy groups is esterified by an aliphatic C^6-20-carboxylic acid that is optionally singly or doubly unsaturated, or i3 etherified by an aliphatic ^12-18-^0°1101 is optionally singly or doubly unsaturated, and the other of the radicals R^ and represents hydroxy, lower alkoxy, amino, lower alkylamino or aminocarbonyl-lower alkylamino, and the use of pharmaceutically acceptable salts of such compounds· The invention relates most preferably to the use of compounds of the formula I that have at an asymmetrically substituted C(-R^)-atom the (D)-configuration, at an asymmetrically substituted C(-E^)-atom the (L)-configuration and at the C.(-U-R8)-atom the (D)configuration, and in which the sugar moiety is derived from (D)-glucose, X1 represents the group UH, X2 represents oxygen, R1, R^, R^, fi8, R10, R12 and R1^ each o represents hydrogen, R represents lower alkyl or phenyl, each of R^ and r\ independently of the other, represents hydrogen or methyl, R6 represents C, ,q ii X—4 alkyl, R represents amino and R represents a radical of the formula . II ι (—NH—u -C )r-NH-CH2-CH2-O-P-O-CH2 in which £ represents 0 or 1, U3, of the formula OH CH-O-Ra1 b CH2-Q-R represents a radical H-C CH.
CH-CH. Γ3 -CH(L) CHV CH-CH.
» ' -CH— Γ2 -CH— (L) or CH\2 CH-CH.
-CH— (L) a h and each of R and R , independently of the other, represents the acyl radical of a saturated aliphatic carboxylic acid having from 12 to 22 carbon atoms or of an unsubstituted aliphatic carboxylic acid having from 12 to 22 carbon atoms and containing one or two double bonds, and the use of pharmaceutically acceptable salts of such compounds* The invention relates above all to the use In accordance with the invention of the following compounds : the sodium salt of B^acetylmuramyl-L-alanyl-D-ieoglutamine-2- (1,2-dipalmitoyl—sn-glycero-4-hydroxyphosphoryloxy)-ethylamide, the sodium salt of N-acetyldesmethylmuramyl-L-alanyl-2"isoglutamine-2-( 1,2-dipalmit oyl-englyoero-3-hydroxyphosphoryloxy)-ethylamide, the sodium salt of N-aeetyldesmethylmuramyl-L-alanyl-g-isoglutamine-2-(l-palmitoyl-2-oleoyl-en-glycero-3*hydroxyphosphoryloxy)-ethylamide, the sodium salt of Nacetyldeamethylmaraayl-Ij-alanyl-D-iBoglutaminyl-Lalanine-2-( 1,2-dipalmitoyl^sn-glycero-3-hydroxyphosphoryloxy)-ethylamlde, N-acetylmuramyl-L-alanyl-Disoglutaminyl-L-alanine-2-(3-palmitoyl-rac-glycero-1hydroxyphosphoryloxy)-ethylaaide, the sodium salt of N-acetylmuramyl—I^-aminobtttyryl-g-ieoglutaminyl-Lalanine-2-(l ,2-dipalaitoyl-sn-glyoero-3-hydroxyphosphoryloxy)-ethylamide, the sodium salt of N-benzoylwuramyl-L-alaayl-D-isoglutaminyl-Ii-alanine-2-(l ,2dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide, N-acetylmaramyl-L-alanyl-D-isoglutaminyl-L-alanine-2(tetradecyloxyfaydroxyphosphoryloxy )-ethylamide, H-acetylmnfaayl-If-alaxiyl-D-isogluteminyl-V-alanine-2(hexadecyloxyfaydroxyphosphoryloxy)-ethylamide, the sodium salt of N-acetylinaramyl-L-a-aminobutyryl-D-ieoglutaminylL-alanlne-2-[ (3R)-hydroxy-(2S)-pal>itoylamino-4toctadecenyloxyhydroxyphosphoryloxy]-ethylamidef the sodium salt of N-acetylmuramyl-L-a-aminobutyryl-Disoglutaminyl-Ir~alaaine-2-[ (3R)-hydroxy-{ 2S)-palmltoylaminooctadecyloxyhydroxyphosphoryloxy]-ethylamide f the sodium salt of N-acetylmiiramyl-I^alanyl-D-ieoglutaminylIf-alaaine-2- (cholest—5-en-3 β-oxyhydroxyphosphoryloxy ]ethylamide, the sodium salt of N-acetylmuramyl-L-O-£(B[2-( 1 -palmitoyl-2-oleoyl-en-glycero-3"hydroxyphosphoryloxy)-ethyl]-succittamoyl)-glyeylJ-aeryl-D-isoglutaalne, the sodium salt of H-acetylnormuramyl-L-O~(l,2-dipalmitoyl-rac-glycero-3-hydroxyphosphcryl)-seryl-J)isoglutamine, the sodium salt of N-acetyl-6-O-([l,2dipalmitoyl-rac-glycero-3-hydroxyphos phoryloxy ]5 acetyl)-norrauramyl-L-danyl-D-isoglutamine , the sodium salt of N-acetyl-6-0-(l, 2-dipalmitoyl-racglycero-3-hydroxyphoephoryloxy)-normuraayl-L-alanylD-isoglutamine» the sodium salt of N-[N-[2-(l,2d ipalmi toyl-sn-glycero) -3-hydroxyphos phoryloxy ]lo ethyl^-succinamoylmuramyl-Ij-alanyl-D-isoglutaraine, the sodium salt of H-acetyl-6-0-[H~[ 2-(1,2-dipalmit oyl-sn-glyc ero-3-hydroxy phosphoryloxy) -ethyl ] succinamoyl^ -muramyl-L-o-aminobutyryl-D-isoglutamine, the sodium salt of R-acetylnormuramyl-L-O-[N-[2-tetra15 decyloxybydroxyphosphoryloxy)-ethyl]-succinamoyl3 seryl-D-isoglutamine, the sodium salt of H-acetylmuramyl-L-O- [[R-(l-palmitoyl-2-oleoyl-sn-glycero-3'" hydroxy phosphoryloxy ) -ethyl ] -succ inamoy 1-L-pheny lalanylj -seryl-D-isoglutamine, the sodium salt of R-acetyl20 muramyl-L-O- (hexadecy loxyhydroxyphosphoryl) -seryl-Disoglutamine and the sodium salt of N-acetylmuramylL-0-(l, 2-dipalraitoyl-3-sn-glyeerohydroxyphosphoryl )seryl-D-isoglutamine.
The invention relates especially to the use of the compounds of the formula 1 described in the Examples, and of the pharmaceutically acceptable salts thereof, and above all to the use of H-acetylmuramylL-alanyl-D-isoglutaminyl-^-alanine-2-( 1,2-dipalmitoylsn-glycero-3-hydroxyphosphoryloxy ) -ethylamide, espe30 daily the sodium salt of this compound, referred to hereinafter as compound I· The following Examples illustrate the invention but do not limit the invention in any way.
Example 1: Groups of 30» 40 or 50 female MF-2f SPF mice each 5 having a body weight of 14-16 g, or of 12-14 g in the case of tests with herpes simplex 1 viruses» are infected intranasally, under light anaesthesia using a mixture of equal parts of ether» ethanol and chloroform» with lethal doses (approximately number of IO plaque-forming units [PFU] see Table 1) of the under- mentioned virus strains in the form of 0.05 ml in each case of a suspension of the viruses.
At the time indicated below (days) in relation to the day of infection, 10 or 20 of these mice are administered once (single dose) the quantities indicated in Table 1 of the active ingredient, the sodium salt of N-acetylmuramyl-^-alanyl-D^isoglutaminyl-t^-alanine-2- (1,2-dipalmitoyl-sn-gLycero-3hydroxyphosphoryloxy)-ethylamide (compound I), in 0.05 ml or 0.1 ml of phosphate-buffered salt solution (PBS) or in 0.2 ml of a 0.05 % by weight solution of sodium carboxymethylcellulose in double-distilled water, by means of intranasal, intravenous or oral administration respectively, in the manner indicated in Table 1.
The remainder of the above-mentioned mice, that is 20 or 30, serve as the control, that is to say they either receive no treatment or are given a placebo.
The intranasal administration of compound I is 30 effected under light anaesthesia using a mixture of equal parts of diethyl ether, ethanol and chloroform.
Table 1 Virus [PFU] Mode of administration Time of administration [days] - : before infection + : after infection Perceni in dep< [mg/kg statist 500 ;age of sndence. 1 Lical si 1OO mice sv on the gnifica 20 trviving quantxt ince XP< IO 20 day y of ac = 0.05, 1‘rs afte :tive i ’"p-O 0.1 r infection ng red lent .Ol (Vierfelder test) O » control Influenza A/ Victoria/3/75 (H3N2) (mouse adapted) [2xlO3-lxlO4 PFU] 1 intravenous -7 80** 90** 30 20 -5 80« 80« 30 -1 80« ao« 7OX 0 90« 1OO« 70* - +1 90« 7OX 60 intranasal -14 60 7O(X> 8OX 40 -7 ioo« 100** 80X oral ! +3 70« 90** 80« 15 1 +7 1OO« ioo« 70« »u Table 1: (continuation) Virus [PFU] Mode of administration Time of administration [days] - : before infection + : after infection Percentage of mice surviving 20 days after infection in dependence on tbe quantity of active ingredient [mg/kg] statistical significance P£ 0.05, 500 100 Influenza ft/ intravenous 66' USS (H1N1 (mouse* adapted) [3x10^-1x10' PFU J XX 50' xx.
PX0.01 (Vierfelder test) 0.1 control XX +2 +6 100' XX xx XX xx XX Influenza A/ Texas/1/7 7( H^Nj (mouse-adapted) [2x10°-lxio1 PFU] intranasal xx 40' (X) 1OO oral +7 (x) XX XX Continuation of Table 1 Virus [PFU] Mode of administration Application time Percent 500 age aur\ 1OO 'Ivors 20 10 1 0.1 0 Influenza B / Hong Kona/5/72 [3xlOS-lxlO6 PPU] intravenous -7 9OX 70 70 42 -5 90* 100" 8O(X) -2 loo** 9OX lOO** -1 loo** 9OX 8Oix) o 100" 1OO** 9OX +1 80*χϊ 8Ο*ΧΪ 60 +2 lOO** 70 9OX +6 lOO™ 8O*x) 70 intranasal -7 100" 60 8OX 30 oral +3 50x 5OX 15 +7 80** 90** 5OX Influenza B / Ann Arbor (Ms·Lu.25.Russ) (mouse-adapted) [lxlo1 PFU] intranasal -14 50X 20 20 O -7 80*" 5OX 20 j oral 43 ICO** 90^ so** I ! 1 15 , 1 1 +7 lOO** i 80** 80** 1 Continuation of Table 1 Virus [PFU] Mode of administration Application time Percentage survivors 500 100 20 10 1 0.1 0 Encephalomyo- carditis [lxloLixio2 PFU] oral o eox lOO** 60 +2 60 80* 90** 30 +4 lOO** 7Otx^ 90** Heroes Simplex l/TUP [2xlO4 PFU] intranasal -7 70X 6OX -_X 60 20 Heroes Simolex l/virtpe intranasal -7 90X 100X 70 40 [2xlO3 PFU] Ml· The course of some of the above-described infections over a period of time is illustrated in Figures 1 and 2. * The great superiority of the phosphoryl compounds of the formula 1 over muramyl peptides, such as N-acetylmuramyl-Ir-alanyl-D^glutamine-n-butyl ester * (compound II) is demonstrated, for example, by the fact that in the case of the above-mentioned tests carried out for comparison purposes, on oral administration of mg of the latter compound on day +7 all the mice die from infection with Influenza A/Texas/1/77, whilst on administration of the same quantity of the phosphorylmuramyl peptide compound I at the same time, as can be seen in the Table, 65 % of the mice survive the infection.
Furthermore, on intranasal administration of 1 mg/kg of compound II on day -7 it is not possible to detect any kind of protective action in the case of infection with Influenza A/Texas/1/77, whilst on administration of the same quantity of compound I at the same time 90 % of the mice survive the infection.
It is also not possible to detect any kind of protective action on intranasal administration of 10 mg/kg of compound II on day -7 in the case of intranasal infection with Herpesvirus hominis 1/TUP, as can be seen from Figure 3.
Example 2 The number indicated in the following Table of female albino guinea pigs of the Pirbright strain <150— 180 g body weight) are infected intravaginally with λ/IO4 PFU (plaque-forming units) of Herpesvirus hominis 2/Angelotti, cultivated in HEL (human χ V* embryonal lungs) cells, as described in B. Lukas et al,. Arch. ges. Virusforsch. 44, 153—155 (1974).
At the time indicated in the following Table (the XO time difference in days in relation to the day of infection, - [minus] indicating a time before infection) the number N of guinea pigs indicated in Table 2 are treated intravaginally with a single dose of in each case 0.1 ml of a gel containing the concentration of comppund I indicated in Table 2.
The gel without active ingredient has the following composition: 2.25 ft sodium carboxymethylcellulose (Hercules, USA) 2o 10 ft glycerine made up to 100 ft with bi-distilled water.
The effect of the treatment can be seen in Table 2.
The symptoms occurring in untreated animals are 25 described in B. Lukas et al., Arch. Virol. 49, 1-11 (1975).
Table 2 Effect on local synqptoras in the topical chemotherapy of Herpes genitalis in guinea pigs (statistical significance XP< 0.05, <.0.01 in the Fisher test) Active ingredient concent rat ion w Treatment time [daya] N Animals [%] with regression of symptoms of > 66% on day Symptom-free animals [%] on day 10 12 14 21 34 7 10 12 14 1.0 -7 14 29 79« 71« 93« 21 57X 86« 86X 100X 0.1 -7 14 21 57x 86** 1OO« 43x 64« 86« 86** 1OO« 1.0 +4 14 79« 79« 86« 93« 36 64« 79** 86« 1OO« 0.1 +4 13 62« es** 1OO« 93** 70** 77« 85« 1OO« loo** o (placebo) +4 14 o 0 o O O 0 o 0 0 control (untreated) 20 0 0 0 O 0 o o _ o 20 Of o Example 3: Eye drops Compositions compound 1 0.10 mg boric acid 30.00 mg sodium tetraborate. 0. 10 mg benzalkonium chloride 0.20 mg water for injection to make up to 1.00 ml Preparation: The boric acid, sodium tetraborate and IO benzalkonium chloride are dissolved while stirring at room temperature under aseptic conditions in a portion of' the above-mentioned quantity of water for injection. CGP 19835 is then dissolved in the resulting solution, and water for injection is added to make up to the final volume of 1.0 ml.
The solution, or a portion or a multiple thereof, is filtered through a membrane filter and introduced into cleaned containers. Suitable containers are, for example: - flexible plastics containers (5 ml or 10 ml) having a dropping attachment, - glass containers (5 ml or 10 ml) having a glass of plastics dropping pipette and an elastomeric pipette filler, or - plastics single-dose pipettes (contents 1 - 2 drops).
I Example 4: Non-aqueous single dose for nasal administration.
♦ Composition: compound I 0.03 mg * Miglyol 812 to make up to 30.00 mg Preparation: 0.03 mg of compound I is dissolved under aseptic conditions in 29.97 mg of Miglyol 812.
This solution is introduced into a commercially IO available single-dose nasal applicator, for example an applicator according to US Patent No. 3 739 951, which is attached to an aerosol-container before use.
Example 5: Nose drops: Composition: I II compound I 0.15 mg 0.10 mg thiomersal 0.02 mg - sodium monohydrogen phosphate.2h20 0. 30 mg 0.30 mg sodium dihydrogen phosphate· 121^0 10 · 10 mg 10.10 mg benzalkonium chloride - 0.10 mg disodium salt of ethylenediaminetetraacetic acid (EDTA) 0.50 mg 0.50 mg sodium chloride 3.70 mg 4.50 mg demineralised water 988.30 mg 987.60 mg pH value: 5.0 i 0.3 5.0 ± 0. lowering of freezing point At - 0.5I°C - 0.56°C Preparation: While stirring at room temperature, the sodium dihydrogen phosphate, disodium monohydrogen phosphate, sodium chloride, thlomersal and the disodium salt of EDTA are dissolved in a portion of the above-mentioned quantity of demineralised water Compound I is then dissolved in this solution and the whole is supplemented with the remaining demineralised water.
The solution, or a portion or a multiple thereof, is filtered through a membrane filter and introduced into cleaned containers.
Suitable containers are, for example: a) glass or plastics containers (5 ml or 10 ml) having a glass or plastics pipette with an elastomeric pipette filler b) compressible plastics bottles having a central tube and a plastics spraying head • c) single-dose plastics containers (contents 2-3 drops), or * glass or plastics bottles that are provided with a standardised pumpable dosing spray made of plastics (no propellant).
Example 6: Gel Composition: compound I 0.01 9 glycerine 85 ft 10.00 9 methyl paraben 0.12 9 propyl paraben 0.03 9 sodium carboxymethylcellulose (high viscosity) 2.50 9 demineralised water 87.34 9 Preparation: The methyl paraben and propyl paraben are dissolved in a portion of the hot demineralised water.
The sodium carboxymethylcellulose is then incorporated into the resulting solution while stirring vigorously, while stirring, the glutinous product is allowed to swell. After cooling, the glycerine and a solution of the active ingredient, compound 1, in the remaining water are then added to this product. » Example 7: Cream Compositions f/5 compound 1 0.10 9 sorbitan monostearate 0.60 9 cetyl alcohol 3.00 9 isopropyl palmitate 2.00 g methyl paraben 0.12 g paraffin oil, viscous 10.00 g PEG (20)-sorbitan monostearate 4.40 g propyl paraben 0.03 g JO % solution of crystalline sorbitol 6.00 9 in demineralised water stearic acid 9.00 g demineralised water 64.67 g · Preparation: The fatty phase, comprising sorbitan monostearate, cetyl alcohol, stearic acid, PEG (20)-sorbitan monostearate, isopropyl palmitate and paraffin oil, is . melted. The methyl paraben and propyl paraben are then 20 dissolved in a portion of the hot demineralised water.
The sorbitol solution is added to the aqueous phase. While stirring, the aqueous phase is then added at . approximately 75°C to the fatty phase. The cream base is then allowed to cool while stirring. A solution of the active ingredient, compound I, in the remaining water is then added to the cream base at approximately 40°C.
Example 8: Nasal ointment Compositions compound 1 0.03 g paraffin oil, viscous 20.00 g white petroleum jelly 30.00 g wool fat, anhydrous 40.00 g demineralised water 19.97 g Pr epara t ions The fatty phase, comprising paraffin oil, petroleum jelly and wool fat, is melted. The aqueous solution of the active ingredient is incorporated into the fatty phase at approximately 50°C.
·# Example 9: Skin ointment Composition compound 1 0.25 g sorbitan sesquioleate 10.00 g white beeswax 5.00 g cetyl alcohol 2.50 g methyl paraben 0. 15 g paraffin oil, viscous 20.00 g propyl paraben 0.02 g stearyl alcohol 2.50 g white petroleum jelly 40.00 g demineralised water 19.58 g Preparation: The fatty phase, comprising sorbitan sesquioleate, white beeswax, cetyl alcohol, paraffin oil, stearyl alcohol and white petroleum jelly is melted. The methyl paraben and propyl paraben are then dissolved in the main quantity of the water at elevated temperature.
• The aqueous phase is incorporated into the fatty phase at approximately 80°C. A solution of the active ingredient, compound I, in the remaining water is added • to the resulting ointment base at approximately 40°C.
Example 10; Lipstick Composition; compound 1 1.00 g polyethylene glycol having an average molecular weight of 400 15.00 g polyethylene glycol having an average molcular weight of 1000 83.00 g polyethylene glycol having an average molecular weight of 4000 1.00 g Preparation: The active ingredient is finely dispersed in the molten polyethylene glycols. The viscous melt is poured into suitable lipstick cases and left to harden.
- Example Us Preparation of compound I A solution of 1.5 mmol of N-acetylmuramyl-L-alanylD-isoglutaminyl-L-alanine-N-hydroxysuccinimide ester in 5 ml of dimethyl acetamide is added dropwise to a solution of 1 mmol of 2-(1,2-dipalmitoyl-sn-glycero-3hydroxyphosphoryloxy)-ethylamide and 3.5 mmol of N' ethyImorpholine in 25 ml of chloroform:methanol:water » 65:25:4. After stirring for 8 hours at room temperature the reaction is complete. 130 ml of water are added to the reaction mixture. Chloroform and portions of the methanol are distilled off under reduced pressure. The aqueous solution is filtered through a millipore filter made of Teflon (pore size 5 um). The filtrate is dialysed, while stirring, in an Amicon ultrafiltration cell through an Amicon YM 10 membrane in a diafiltration process firstly against water (400 ml), then against 0.1M sodium phosphate buffer - 0.1M NaCl, pH 7 (200 ml), and subsequently against water (850 ml). The internal dialysate is filtered through a millipore filter, pore size 0.45 um, and freeze-dried, yielding the sodium salt of N-acetyl15 muramyl-L-alanyl-D-isoglutaininyl-I^-alanine-2- (1,2dipalraitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide hydrate.
I Example 12: Groups of 20 female Tif:MF-2f (SPF) mice each having a body weight of 14-16 g are infected intravenously, under light anaesthesia using a mixture of equal parts of diethyl ether, ethanol and chloroform, with 2 χ 103 PFU vaccinal virus IHD in the form of in each case 0.1 ml of a suspension of the virus in beef heart infusion broth. of these mice from each of the above-mentioned groups are treated on the fourth or sixth day after infection, that is to say on day +4 or +6 (administration day), with a single oral administration of 1 mg/kg of compound I in 0.2 ml of a 0.05 % by weight aqueous solution of sodium carboxymethylcellulose.
The remaining 10 mice from each of the abovementioned groups serve as the controls and receive a 9 placebo.
On the seventh, ninth, tenth and twelfth day after infection the number of tail lesions in the mice is determined, this being carried out substantially as described by J.J. Boyle, R.F. Haff and R.C. Stewart in Antimicrobial Agents and Chemotherapy, 536-539 (1966), and it should be noted that the first tail lesions can be identified only on the sixth or seventh day. The results can be seen in Table 3: Table 3s Day of administration Number of tail lesions (mean + standard deviation) on day +7 +9 +1O +12 +4 0.9+0.7* 0.9+0.9* 0.9+1.4* O.2+0.4* +6 1.1+1.4* 0.9+1.6* 0. 3+0.7* 0.5+1.0* control 4.3+1.9 4.3+1.9 5.9+1.9 4.6+1.8 * statistical significance P< 0.01 (Student's T-test) Example 13: Groups of 50 - 54 female albino guinea pigs of the Pirbright strain (150—180 g body weight) are infected intravaginally with 1 χ 103 PFU of the neurotropic virus strain Herpes simplex 2/MS in a manner analogous to Example 2. In the case of the Alabama strain, on the third day after infection 15 to 18 of these guinea pigs are administered orally a single dose, as indicated in Figure 4, of compound I in 0.2 XO ini of a 0.005 % by weight aqueous solution of sodium carboxymethylcellulose. In the case of the MS strain, . on the seventh day before infection 17 to 19 of the above-mentioned guinea pigs, under light anaesthesia using a mixture of equal parts of diethyl ether, X5 ethanol and chloroform, are administered intranasally a single dose, as indicated in Figure 5, of compound 1 in 0.2 ml of a 0.005 % by weight aqueous solution of sodium carboxymethylcellulose.
The control groups each comprise 35 animals and 2o. receive no treatment (Fig. 4) or are given a placebo (Fig. 5). The results are shown in Figures 4 and 5, respectively.
Example 14: Groups of 30 or 34 female Tif:MF 2f (SPF) mice 25 each having a body weight of 14-16 g are infected intranasally under light anaesthesia with from 10 to 50 PFU of Parainfluenza Virus 1 (Sendai)/52 (mouseadapted, stored at -70°C in the form of a mouse-lung suspension in ampoules). For the above-mentioned 30 anaesthesia there is used a mixture of equal parts of diethyl ether, alcohol and chloroform.
At the time indicated in Figures 6 and 7, 10 (in the case of Fig. 6) and 14 (in the case of Fig. 7) of these mice are administered once the quantities indicated in the Figures of compound I in 0.2 ml of 0.005 % by weight sodium carboxymethylcellulose in double-distilled water in the manner indicated in the , Figures, in the case of intranasal administration of the active ingredient before infection under anaesthesia using a mixture of equal parts of diethyl ,, ether, alcohol and chloroform and in the case of intranasal administration of the active ingredient after infection under anaesthesia using Nembutal (0.5 IO mg/mouse, intraperitoneal), followed after 20-25 minutes by intranasal administration by drip of 0.02 ml of 1 % aqueous clnchocaine hydrochloride solution.
The remaining 20 mice from each of the above-mentioned groups serve as the control. The control animals either receive no treatment or are given a placebo.
The action of compound 1 can be seen from Figures 6 and 7.
Example 15: Groups of 30 female Tif:HF-2f (SPF) mice having a body weight of 14-16 g are infected intranasally under light anaesthesia, using a mixture of equal parts by volume of diethyl ether, ethanol and chloroform, with lethal doses (approximately LDgQ_g0) of the virus strains indicated in Table 4. At the time shown in Table 4 [days in relation to the day of infection] 10 of these mice in each case are administered once (single dose) with the quantity, the active ingredient, n . and in the manner of administration, all as indicated in Table 4.
The active ingredients are: * the sodium salt of N-acetyl-6-0-{[N-2-(1,2-dipalmitoylsn-glycero-3-hydroxyphosphoryloxy)-ethyl]-succinamoyl^normuramyl-L-alanyl-D-isoglutaraine (III), · ί·3 the sodium salt of N-propionyldesmethylmuramyl-Lalanyl-D-isoglutarainyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide (IV), 5 the sodium salt of N-acetyl-1,4,6-0-triacetylmuramyl-L^alanyl-D^isoglutaminyl-L-alanine-2(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide (V), the sodium salt of N-acetylmuramyl-L-alanyl10 D-isoglutamine-2-(1,2-dipalmitoyl-sn-glycero-3hydroxyphosphoryloxy)-ethylamide (VI), and the sodium salt of N-acetylmuramyl-L-alanylD-isoglutaminyl-y-oxymethylcarbonyl-2-(1,2dipaImitoyl-sn-glycero-3-hydroxyphosphoryloxy)15 ethylamide (VII)· The remaining 20 mice in each group serve as the control, that is to say instead of the active ingredient they receive a placebo (0.005 % by weight of . sodium carboxymethylcellulose in double-distilled 2o water).
The results of the test are shown in Table 4.
Table 4 Active ingredient Virus Mode of administration Time of administration Percentage of mice surviving 23 days after infection in dependence upon the quantity of active ingredient [mg/kg] 1OO 10 1 0.1 0 (placebo) III Influenza A/Texaa/1/77 3n2) oral +7 60 60 60 30 IV Influenza A/Texaa/1/77 (h3»2) oral +7 60 30 V Influenza A/Texas/1/77 (h3n2) oral +7 50 40 15 VI Influenza A/Texas/1/77 (h3n25 oral +7 60 60 80 15 VII Influenza A/Texas/1/77 (h3n2) oral +7 60 40 15 Example 16: Manufacture of 1000 tablets containing 0.5 ft of active ingredient Composition for 1000 tablets: compound I 0.5 g lactose, ground 43.0 g corn starch 52.0 g Pharmacoat 603® (hydroxypropyl- 3.0 g methylcellulose containing 28-30 % methoxy groups, supplied by Shinetsu Chemical Company, Tokyo, Japan) Aerosil® (colloidal silica, supplied 1.0 g by oegussa, Frankfurt, Federal Republic of Germany) magnesium stearate 0.5 g Preparation: Compound 1 and )5 g of lactose are premixed. The resulting premix is mixed with 28 g of lactose and 47 g of corn starch. Using the resulting mixture and an aqueous solution of the Pharmacoat a composition suit20 able for granulation is prepared and is granulated, dried and ground. 5 g of corn starch, the Aerosil and magnesium stearate are mixed in and the whole is pressed to form 1000 tablets each weighing 100 mg.
The compacts can be provided with a coating that is resistant to gastric juices in a manner known per se.
Example 17: Active ingredient in the form of a dry lyophilised substance 0.5 mg of compound I and 500 mg of mannitol GO (pyrogen-free) are dissolved in water for injection and sterile-filtered through a membrane filter. The sterile-filtered solution is introduced under aseptic conditions into a sterilised glass ampoule or into a glass phial and freeze-dried. After lyophilisation the ampoule is sealed or the phial is sealed with a rubberelastomeric seal and aluminium cap.
Example 18; Single-dose pipette with nose drops A 0.05 % solution of compound 1 in 1,2-propylene glycol, benzyl alcohol or ethanol or in a mixture of 1,2-propylene glycol and polyethylene glycol having an average molecular weight of 300 is prepared.
The solution is filtered and introduced into single-dose pipettes made of deformable plastics. The single-dose pipettes contain the quantity of nose drops required for one application, that is to say they each contain 0.1 ml of the above solution.
Claims (33)
1. · A pharmaceutical composition for enteral or parenteral application, which composition contains, aa sole active ingredient, an effective amount, but less than 1 Z by weight, of a compound of the 5 formula X in which the sugar moiety la derived from (D)-galactose, (D)-mannooo or (D)-glucose, which compound has at an asymmetrically substituted 3 C(-R ) atom the (D)-configuratlon, at an asymmetrically substituted IO C(-R^) atom the (L) -configuration and at an asymmetrically substig tuted C(-R ) atom the (D)-conflguratlon, and in which compound 1 2 ~ each of X and X independently of the other represents a group of the formula -0- or -N(R 14 )-, R 14 representing 12 12 13 hydrogen or lower alkyl, each of R , R , R and R 15 independently represents a radical of the formula la -(•zW-X^n-A 1 (Ia) in which n represents 0 or 1, Z 1 represents carbonyl or thiocarbonyl, Y 1 represents unsubstituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, X represents a group of the formula -0- or 14 14 -N(R )-, wherein R has the meaning given above, and A represents a radical of the formula Ib P-O-R OH in which represents radical having at least group of the formula Ic (Ib) an aliphatic or cycloaliphatic 7 carbon atoms, or A^ represents a 0 R 16 Π I -P-O-CH 1 *17 OH R ' in which R^® represents (Ic) hydrogen and R^ 7 represents 2. -hydroxyethyl or 1,2-dihydroxyethyl, wherein at least onq hydroxy group is esterified or etherified by a radical having at least 7 carbon atoms, or In which each of R 1 ® and r!7 independently of the other represents esterified or etherified hydroxymethyl, the esterifying or etherifying 1 2 radicals having at least 7 carbon atoms, or each of R , R , 12 13 R . and R independently represents hydrogen, acyl other than a radical of the formula Ia in which n represents 1, or aliphatically substituted silyl, each of R^, R 4 R 5 , R 7 8 6 and R° independently represents hydrogen or lower alkyl, R° represents hydrogen or lower alkyl that is unsubstituted or substituted by a group of the formula Id 2 2 A 7 -Ε-(Ζ Ζ -Υ-χ\-Α Ζ (Id) in which m represents 0 or 1, E represents a group of the formula -0-, -S- or -N(R^ 4 )-, R^ 4 having the meaning given 2 ‘2 above, Z represents carbonyl or thiocarbonyl, Y represents unsubstituted or substituted alkylene which may 4 be interrupted by iminocarbonyl or oxycarbonyl, X 14 14 represents a group of the formula -0- or -N(R )-, R 2 5 having the meaning given above, and A represents a radical . of the formula lb or Ic; pr by free or etherified hydroxy or mercapto, by esterified hydroxy or mercapto other than a group of* the formula Id, by free amino or substituted amino other than a group of the formula Id, by free, IQ esterified or amidated carboxy, by cycloalkyl, by carbocyclic aryl or by nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring, or R 5 and R^ together represent unsubstituted or substituted 1,3- or 9 11 1,4-lower alkylene, each of R and R independently of 15 the other represents a radical of the formula Ie -X 5 -Y 3 -X 6 -A 3 (Ie) in which X^ represents a group of the formula -0-, -S- or and Χθ represents a group of the formula -0- or -N(rI^)-, in each case R^ having the meaning given abovej 3 20 Ύ represents unsubstituted or substituted alkylene which may.be interrupted by iminocarbonyl or oxycarbonyl, and A represents a radical of the formula lb or Ic, or free hydroxy pr mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or 25 substituted amino other than a radical of the formula le, . and represents hydrogen or free, esterified or amidated carboxy, with the proviso that radicals qualified by the term ’’lower 11 contain up to and including 7 carbon atoms and that the compounds of the formula I have at least one 30 radical A , A or A and/or a pharmaceutically acceptable salt thereof, together with a pharmaceutical carrier.
2. A composition according to claim 1, which contains a . 1 2 12 compound of the formula 1. in which each or R , R , R and R independently represents hydrogen, the acyl radical of an aliphatic, cycloaliphatic, aromatic or araliphatic carboxylic acid having up to 90 carbon * atoms, tri-lower alkylsilyl, or a radical of the formula Ia in which ri and X 3 have the meanings given in claim 1, represents carbonyl, Y^ represents lower ( alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, and A^ represents a radical of the formula lb or Ic in which represents an aliphatic 1 β radical having at least 7 carbon atoms, R represents hydrogen and represents 2-hydroxyethyl or 1,2dihydroxyethyl, in which at least one hydroxy group is etherified by an aliphatic radical having at least 7 and up to 90 carbon atoms or is esterified by a corresponding aliphatic acyl radical, or each of and R?\ independently of the other, represents hydroxymethyl etherified by an aliphatic radical having at least 7 and up to 90 carbon atoms or esterified by a corresponding aliphatic acyl radical, R 6 represents hydrogen or lower alkyl that is unsubsituted or substituted by a radical of the formula Id in which m, E and have the meanings given in claim 1, Z 2 represents carbonyl, Y represents lower alkylene which may be Interrupted by iminocarbonyl or oxycarbonyl, and A 2 represents a radical of the formula lb or Ic in which R^ 5 represents an aliphatic radical having at least 7 carbon atoms, R^ represents hydrogen and R 1 ? represents 2-hydroxyethyl or 1,2-dihydroxyethyl, in which at least one hydroxy group is esterified by an aliphatic radical having at least 7 and up to 90 carbon atoms or by a corresponding aliphatic acyl radical, or each of R ie and R 17 , independently of the other, represents hydroxymethyl esterified by an aliphatic acyl radical haying at least 7 and up to 90 carbon atoms, or R 6 represents lower alkyl substituted by hydroxy or 5 mercapto, by hydroxy or mercapto etherified by an aliphatic radical containing up to 90 carbon atoms, by hydroxy or mercapto that is esterified by an aliphatic acyl radical containing up to 90 carbon atoms and is other than the group of the formula Id, by amino, by IO amino that is substituted by an acyl radical containing up to 90 carbon atoms and is other than a radical of the formula Id, by free carboxy, by lower alkoxycarbonyl, by carbamoyl, by lower alkylaminocarbonyl, by carboxy-lower alkylaminocarbonyl or by amidated carboxyl of the 1.5 formula II 2 4 2 -C-E-(Y 2 4 2 in which m, Ε, Υ , X and Λ have the meanings given in claim 1, by phenyl that is unsubstituted or substituted . by hydroxy, lower alkoxy or halogen, or by imidazolyl or 2o indolyl, or R^ and R® together represent 1,3- or 1,4lower alkylene, each of R^ and R^\ independently of the other, represents hydroxy, lower alkoxy, amino, lower alkylamino, carboxy-lower alkylamino, or a radical of the formula Ie, in which X$ and X 6 have the 25 meanings given in claim 1, Y 3 represents lower alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, and A^ represents a radical of the formula lb or Ic, in which R^ represents an aliphatic radical having at least 7 carbon atoms, represents 30 hydrogen and R 17 represents '2-hydroxyethyl or 1,2dihydroxyethyl, in which at least one hydroxy group is etherified by an aliphatic radical having at least 7 and up to 90 carbon atoms or is esterified by a corresponding aliphatic acyl radical, or each of R 16 and R^ 7 , independently of the other, represents hydroxymethyl etherified by an aliphatic radical having at least 7 and up to 90 carbon atoms or esterified by a 5 corresponding aliphatic acyl radical, and R 10 represents hydrogen, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylaminocarbonyl or carboxy-lower alkylaminocarbonyl, with the proviso that the compounds * of the formula I have atleast one radical A 1 , A 2 or A 3 , Lq and/or a pharmaceutically acceptable salt thereof.
3. Λ composition according to claim 1 which contains a compound of the formula I, wherein represents the group NH and 2 1 X. represents oxygen, R represents hydrogen, lower alkanoyl, or a group of the formula Ia in which 15 represents 1, Z^ represents carbonyl, Y^ represents lower alkylene which may be interrupted by iminocarbonyl, represents a group of the formula -0- or -NH-, and A^ represents a radical of the formula lb or Ic in which r15 represents an alkyl radical having from 7 to 2o 3.0 carbon atoms that is unsubstituted or substituted by hydroxy., amino and/or alkanoylamino having up to 30 carbon atoms, R^ represents hydrogen and K^ 7 represents 2-hydr0xyethyl or 1,2-dihydroxyethyl, wherein each of the hydroxy groups in a radical R^ 7 , independ25 ently of the other, is etherified by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterified by an alkanoyl radical having from 7 to 90 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or each of R^ and R^ 7 , independently of the other, represents hydroxymethyl in which the hydroxy group is etherified by an alkyl radical having from 7 'to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterif'ied by an 5 alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, R represents lower alkanoyl, hydroxy-lower alkanoyl, benzoyl, or a group of the formula Ia in which ii, z\ χθ ' X 3 and have the meanings given hereinbefore in this claim, R^ 2 represents hydrogen or lower alkanoyl, R 13 represents hydrogen, alkanoyl or hydroxyalkanoyl having up to 90 carbon atoms, alkanoylaminoalkanoyl having up to 30 carbon atoms, or a group of the formula X5 la in which ri, z\ X 3 and have the meanings given hereinbefore in this claim, R 3 and R 7 .each represents hydrogen or methyl, R 4 , R 5 , R® and R 10 each represents hydrogen, R® represents hydrogen, lower alkyl that is unsubstituted or substituted by free hydroxy or 2q mercapto, lower alkoxy, lower alkylthio, alkanoyloxy or hydroxyalkanoyloxy having up to 90 carbon atoms, or by phenyl, imidazolyl or indolyi, or by a group of the formula Id in which m represents 1, E represents a ο group of the formula -O- or -S-, Z represents carbonyl, 25 Y 2 represents lower alkylene which may be interrupted by iminocarbonyl, represents a group of the formula -0-, and A 2 represents a radical of the formula lb or Ic in which represents an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or 3q substituted by hydroxy, amino and/or alkanoylamino haying up to 30. carbon atoms, R^ represents hydrogen, and R 17 represents 2-hydroxyethyl or 1,2-dihydroxyethyl, wherein each of the hydroxy groups in a radical R^ 7 , independently of the other, is etherified by an 35 alkyl radical having from 7 to 30 carbon atoms that is Λ 7 4 unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterified by an alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or each of R 1 ^ and R 17 , independently of the other, represents hydroxymethyl in which the hydroxy group is etherified by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterified by an alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, and each of the radicals R 9 and R^\ independently of the other, represents hydroxy, lower alkoxy, amino, lower alkylamino, carboxy-lower alkylamino, or a radical of the formula Io in which represents a group of the formula -0- oc -Nil-, Y 3 represents lower alkylene which may be interrupted by iminocarbonyl, X^ represents a group of the formula -0- and Λ 3 represents a radical of the formula Ib or Lc in which R?5 represents an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, R^ represents hydrogen and R 33 represents 2-hydroxyethyl or 1,2-dihydroxyethyl, wherein each of the hydroxy groups in a radical R 17 , independently of the other, is etherified by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterified by an alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or each of R 3 ® and R^ 7 , independently of the*other, represents hydroxymethyl in which the hydroxy group is etherified by an alkyl radical having from 7 to 30 carbon atoms that is unsubstituted or 5 substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, or is esterified by an alkanoyl radical having from 7 to 90 carbon atoms that is unsubstituted or substituted by hydroxy, amino and/or alkanoylamino having up to 30 carbon atoms, with the 10 proviso that the compounds contain at least one radical selected from the group A 1 , A 2 and A 3 , and/or a pharmaceutically acceptable salt thereof.
4. A composition according to claim 1 which contains a compound of the formula 1, wherein 15 . χΐ represents a group of the formula -N(R 14 )-, R 14 representing hydrogen or Cj -4 -alkyl, ·? 1 X represents oxygen, R represents hydrogen, lower alkanoyl, or a group of the formula T.a in which ri reposonts 0 or 1, represents carbonyl, Y^ 20 represents lower alkylene which may be interrupted by imihocarbonyl, X 3 represents oxygen, and A^ represents a radical of the formula lb or Ic in which R^ represents an alkyl or alkenyl radical having from 7 to 30 carbon atoms that is unsubstituted or substituted by 25 hydroxy, amino and/or alkanoylamino having up to 22 carbon atoms, R^ represents hydrogen and R 17 represents 2-hydroxyethyl or 1,2-dihydroxyethyl, at least one hydroxy group in a radical R 17 being etherified by an alkyl or alkenyl radical having from 7 30 to 30 carbon atoms, or being, esterified by an alkanoyl or alkenoyl radical having from 7 to'30 carbon atoms, or each of R 16 and R 17 , independently of the other, . represents hydroxymethyl in which the hydroxy group is etherified by an alkyl or alkenyl radical having from 7 to 30 carbon atoms, or is esterified by an alkanoyl or * 2 alkenoyl radical having from 7 to 30 carbon atoms, R represents lower alkanoyl, hydroxy-lower alkanoyl, benzoyl or, independently of r\ R^ 2 and R^ 3 , a group of 5. The formula Ia as defined hereinbefore in this claim, each of R 3 , R 4 , R 5 , R 7 and R 8 independently represents hydrogen, methyl or ethyl, R® represents hydrogen, or lower alkyl that is unsubstituted or substituted by free hydroxy, free mercapto, IO lower alkoxy, lower alkylthio, alkanoyloxy having from 2 to 30 carbon atoms, alkenoyloxy having from 6 to 30 carbon atoms, phenyl, 4-hydroxyphenyl, or by a group of the formula Id in which m represents 0 or 1, E represents oxygen or sulphur, Ζ Λ represents carbonyl, Y 15 represents lower alkylene that is unsubstituted or substituted by phenyl and may be interrupted by iminocarbonyl, X 4 represents oxygen and A 2 , independently of A^ and A 3 , represents a radical of the formula lb or Ic as defined hereinbefore in this q ii 20 claim, each of R and R, independently of the other, represents hydroxy, lower alkoxy, amino, lower alkylamino, carboxy-lower alkylamino, lower alkoxycarbonyl-lower alkylamino, carbamoyl-lower alkylamino, or a radical of the formula Ie in which X 5 25 represents oxygen or NH, Y 3 represents lower alkylene which may be interrupted by iminocarbonyl, X® represents oxygen and A 3 , independently of A^ and A 2 , represents a radical of the formula lb or Ic as defined hereinbefore in this claim, R^® represents 30 hydrogen, r' 2 represents hydrogen, lower alkanoyl or the same radical as R^ 3 , and R^ 3 represents hydrogen, or alkanoyl or alkenoyl each having up to 30 carbon atoms or, independently of R^ and R 2 , a radical of the formula Ia as defined hereinbefore in 35 this claim, with the proviso that the compounds contain at least one, and at most two, radical selected from the 12 3 group A , A and A , and/or a pharmaceutically acceptable salt thereof.
5. A composition according to claim 4, which 3 contains a compound of the formula I, 1 2 wherein X represents the group NH, X represents oxygen, represents hydrogen or lower alkanoyl, represents lower alkanoyl, benzoyl or a group of the formula Ia in which in represents 0 or 1, IO Z^ represents carbonyl, Y^ represents lower alkylene which may be interrrupted by one or two iminocarbonyl groups, X^ represents oxygen, and represents a radical of the formula lb or Ic in which R^ represents an alkyl radical having from 7 to 22 carbon atoms, R 16 15 represents hydrogen, and R^ 7 represents 1,2-dihydroxyethyl in which each of the hydroxy groups, independently of the other, is esterified by an alkanoyl or alkenoyl radical having From 10 to 22 carbon atoms, R 3 represents hydrogen or methyl, R^, R 5 , R 7 and R® each 20 represents hydrogen, R® represents hydrogen, or lower alkyl that is unsubstituted or substituted by free hydroxy, alkanoyloxy having from 2 to 22 carbon atoms, alkenoyloxy having from 6 to 22 carbon atoms, phenyl or by a group of the formula Id in which m represents 0 or 25 1, E represents oxygen, Z 7 represents carbonyl, Y^ represents lower alkylene that is unsubstituted or substituted by phenyl and may be interrupted by iminocarbonyl, X^ represents oxygen and A^, independently of A and A, represents a radical of the above-defined 50 formula lb or Ic, each of R 9 and R^, independently of the other, represents hydroxy, lower alkoxy, amino, lower alkylamino, α-carboxy-lower alkylamino, ot-lower alkoxycarbonyl-lower alkylamino, a-carbamoyl-lower alkylamino, or a radical of the formula Ie in which X 5 35 represents the group NH, Y 3 represents lower alkylene which may be interrupted by one or two iminocarbonyl groups, X® represents oxygen and A 3 , independently of A^- and A 2 , represents a radical of the formula lb or Ic defined hereinbefore, represents hydrogen, R^ 2 5 represents hydrogen, lower alkanoyl or the same radical as R 13 , and R 13 represents hydrogen, alkanoyl having from 2 to 22 carbon atoms, alkenoyl having from 6 to 22 caibon atoms or, independently of R 2 , a radical of the formula Ia as defined hereinbefore, and/or 10 a pharmaceutically acceptable salt thereof.
6. A composition according to claim 5, which contains a compound of the formula I, 1 2 wherein X represents the group NH, X represents oxygen, R^ represents hydrogen or C 2 _4 alkanoyl, R represents G 2 _4-alkanoyl or a group of the formula Ia in which r\ represents 0 or 1, represents carbonyl, Y 1 represents lower alkylene which may be interrupted by one or two iminocarbonyl groups, X 3 represents oxygen, and A^ represents a radical of the formula lb or Ic in which represents an unbranched alkyl radical having from 12 to 18 carbon atoms, R^ 6 represents hydrogen and R^ 7 represents 1,2-dipalmitoyloxyethyl or 2-oleoyloxy-1-palmitoyloxyethyl, R 3 represents hydrogen or methyl, r\ r\ r 7 f r® and each represents hydrogen, r6 represents methyl, ethyl or isopropyl, each of which is unsubstituted or substituted by a retdical of the formula Id in which m represents 0 or 1, E represents oxygen, Z 2 represents carbonyl, Y 2 represents lower alkylene that is unsubstituted or substituted by phenyl and may be interrupted by one or two intinocarbonyl groups, represents oxygen and A 2 , independently of A^ and A 3 , represents a radical of the formula lb or Ic defined hereinbefore, R^ represents amino, R^ represents hydroxy or a radical of the formula ie in which X 5 represents the group NH, Y 3 represents lower alkylene which may be interrupted by one or two irainocarbonyl groups, X® represents oxygen and A 3 , independently of A^ and A 2 , represents a radical of the formula lb or Ic defined hereinbefore, R^ 2 represents hydrogen, acetyl or the same radical as R^ 3 , and R^ 3 represents hydrogen, acetyl or, independently of R 2 , a radical of the formula Ia as defined hereinbefore, and/or a pharmaceutically acceptable salt thereof.
7. A composition according to any one of claims 1 to 6 which contains a compound of formula I, in which the 12 3 radicals A ,, A and A , if present, represent a radical of the formula Ic, and/or a pharmaceutically acceptable salt thereof.
8. A composition according to any one of claims 1 to 7 which contains a compound of formula I, in which the sugar moiety is derived from (D)-galactose or (D)-mannose, and/or a pharmaceutically acceptable salt thereof.
9. A composition according to any one of claims 1 to 7 which contains a compound of formula I, in which the sugar moiety is derived from (D)-glucose, and/or a pharmaceutically acceptable salt thereof.
10. A composition according to any one of claims 1 to 9 which contains a compound of formula I that carries only 13 one phosphoryl substituent, namely in the radical R , and/or a pharmaceutically acceptable salt thereof.
11. A composition according to any one of claims 1 to 9 which contains a compound of formula 1 thaL carries only 6 one phosphoryl substituent,, namely in the radical R and/or a pharmaceutically acceptable salt thereof.
12. A composition according to any one of claims 1 to 9 which contains a compound of formula I that carries only one phosphoryl substituent, namely in the radical R^ 1 , f and/or a pharmaceutically acceptable salt thereof.
13. A composition according to claim 1 which contains N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy )ethylamide and/or a pharmaceutically acceptable salt thereof.
14. Λ composition according to any one of claims 1 to 13 which contains a pharmaceutically acceptable salt of a compound of the formula I.
15. A composition according to claim 14 which contains a sodium salt of a compound of the formula I.
16. A compost ion according to claim 1 which contains a compound of formula I that has at an asymmetrically substituted C(-R 3 )-atom the (Ώ)-configuration, at an asymmetrically substituted C(-R^)-atom the (L)-configurfi ation, and at the C(-N-R°)-atom the (θ)configuration, and in which the sugar moiety is derived from (D)glucose, X^ represents the group NH, X 2 represents oxygen, R 1 , R 4 , R 5 , R 7 , R®, R 10 , R 12 and R 13 each represents hydrogen, R 2 represents C-j_ 3 -alkyl or phenyl, R 3 represents hydrogen or C^ -3 -alkyl, R® represents · hydrogen, C^j-alkyl optionally substituted by hydroxy, methoxy, mercapto, methylmercapto or by halogen, phenyl βί or phenylmethyl each optionally substituted by hydroxy, methoxy or halogen, or heterocyclyl or heterocyclylmethyl each containing one or two aza atoms and having 5 ring members, or R 9 and R® together represent trimethylene, 5 one of the radicals R 9 and represents a radical of the formula le in which X^ represents the group NH or oxygen, Y 3 represents C 2 _ 3 -alkylene or a radical of the formula 2 3 2 Π 3 -ϋ -COO-U - or -U -C-NH-U -, 10 in which each of and U 3 , independently of the other, represents C^^-alkylene that is unsubstituted or substituted by Cj^-alkyl optionally substituted by hydroxy, lower alkoxy, mercapto or by lower alkylmercapto, or by phenyl or phenyl-lower alkyl each of 35 which is optionally substituted by hydroxy, methoxy or halogen, or by heterocyclyl or heterocyclyl-(C-|_-j_alkyl) each containing one or two aza atoms and having 5 or 6 ring members, X® represents oxygen, and A 3 represents a radical of the formula Ic in which represents 20 hydrogen and R 17 represents a 1,2-dihydroxyethyl or 2-hydroxyethyl group in which at last one of the.hydroxy groups is esterified by an aliphatic Cj 6 _ 2 o-carboxylic acid that is optionally singly or doubly unsaturated, or is etherified by an aliphatic C^2-ig“ a lkohol that is 25 optionally singly or doubly unsaturated, and the other of the radicals R 9 and R^ represents hydroxy, lower alkoxy, amino, lower alkylamino or aminocarbonyl-lower alkylamino, and/or a pharmaceutically acceptable salt . thereof.
17. A composition according to claim 1 which contains a compound of the formula I that has at an asymmetrically substituted C(-R 3 )-atom the (D)-configuration, at an asymmetrically 5 substituted C(-R 6 )-atora the (L)-configuration and at the C(-N-R®)-atom the (D)-configuration, and in which the sugar moiety is derived from (D)-glucose, X^ 2 14 represents the group NH, X represents oxygen, R , R , r\ R 8 , R 10 , r^ 2 and R^ each represents hydrogen, R 2 0 represents lower alkyl or phenyl, each of R 3 and r\ independently of the other, represents hydrogen or methyl, R 6 represents C^-alkyl, R 9 represents 1 1 ammo and R represents a radical of the formula 0 0 (-NH-U 1 -(5) r -NH-CH 2 -CH 2 -O-P-O-CH 2 OH CH-O-R I b CH 2 “O-R 15 in which .r represents 0 or 1, iP represents a radical of the formula CH. V c: CH-CH. CH. \ 2 l 3 CH-CH_ I 3 CH-CH I 1 -CH- , 1 —CH— 1 -CH- or 1 -CH- (L) (L) (L) (D and each of R a and R u , independently of the other, represents the acyl radical of a saturated aliphatic carboxylic acid having from 12 to 22 carbon atoms or of an unsubstituted aliphatic carboxylic acid having from 5 12 to 22 carbon atoms and containing one or two double bonds, and/or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition for topical application according to any one of claims 1 to 19 that contains from 0.001 % up to, but exclusive of, 1 % of active ingredient.
19. Eye drops according to claim 18.
20. Aqueous nose drops according to claim 18.
21. - Anhydrous nose drops according to claim 18.
22. Gel according to claim 18.
23. Cream according to claim 18.
24. Nasal ointment according to claim 18.
25. Skin ointment according to claim 18.
26. - Lipstick according to claim 18.
27. A pharmaceutical composition according, to any one of claims 1 to 17 for oral administration in the form of 20 tablets or capsules with an .active ingredient content of 0.1 to 0.9 % by weight.
28. A pharmaceutical composition according to any one of claims 1 to 17 in dosage unit form having an active ingredient content of 0.1 to 1 mg per dosage unit.
29. A pharmaceutical composition according to any one of 5 claims 1 to 28 for administration to warm-blooded animals for the prophylaxis or therapy of diseases caused by viruses.
30.. Use of a compound of the formula 1 as defined in any one of claims 1 to 17, or of a pharmaceutically acceptable 10 salt thereof, for the preparation of medicaments for administration to warm-blooded animals for the prophylaxis or therapy of diseases caused by viruses.
31. -. Use according to claim 30 for the prophylaxis or therapy of diseases caused by influenza or Herpes simplex 15 viruses.
32. Use according to claim 30 for the prophylaxis or therapy of diseases caused by encephalomyocarditis, vaccinia or para-influenza viruses.
33. A pharmaceutical composition according to claim 1, substantially as hereinbefore described and exemplified.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH452882 | 1982-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE831728L IE831728L (en) | 1984-01-23 |
IE55793B1 true IE55793B1 (en) | 1991-01-16 |
Family
ID=4277773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1728/83A IE55793B1 (en) | 1982-07-23 | 1983-07-22 | Use of sugar derivatives for the prophylaxis and treatment of virus infections |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0102319B1 (en) |
JP (1) | JPS5933297A (en) |
AU (1) | AU566879B2 (en) |
BE (1) | BE897359A (en) |
DE (1) | DE3326163A1 (en) |
HK (1) | HK79890A (en) |
IE (1) | IE55793B1 (en) |
IL (1) | IL69294A (en) |
IT (1) | IT1168778B (en) |
NZ (1) | NZ205000A (en) |
SG (1) | SG77989G (en) |
ZA (1) | ZA835360B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3465087D1 (en) * | 1983-03-04 | 1987-09-03 | Merck & Co Inc | Immunostimulatory dipeptidyl d-glucose derivatives and methods of preparation |
FR2564096B1 (en) * | 1984-05-11 | 1988-02-19 | Anvar | LIPOPHILIC DERIVATIVES OF MURAMYLPEPTIDES HAVING MACROPHAGE ACTIVATION PROPERTIES, COMPOSITIONS CONTAINING THEM AND PROCESS FOR OBTAINING THE SAME |
US4885285A (en) * | 1984-09-13 | 1989-12-05 | Ciba-Geigy Corporation | Phosphorus compounds, processes for their manufacture, and their use |
US4873322A (en) * | 1986-01-24 | 1989-10-10 | Ciba-Geigy Corporation | Saccharide derivatives and processes for their manufacture |
DE4305553A1 (en) * | 1992-12-18 | 1994-06-23 | Rhone Poulenc Rorer Gmbh | Topical pharmaceutical or cosmetic compsn - contg. N-acyl-alkanolamine and phosphatidyl-ethanolamine derivs., e.g. for protecting skin against light or treating insect stings |
GB9419011D0 (en) * | 1994-09-21 | 1994-11-09 | Peptech Uk Ltd | Use of muramyl peptide compounds |
AU2005223715A1 (en) * | 2004-03-22 | 2005-09-29 | Kode Biotech Limited | Synthetic membrane anchors |
MX2023011004A (en) | 2021-03-19 | 2024-01-08 | Trained Therapeutix Discovery Inc | Compounds for regulating trained immunity, and their methods of use. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI75578C (en) * | 1979-07-25 | 1988-07-11 | Ciba Geigy Ag | Analogous procedure for the preparation of pharmacologically acting lipophilic a phosphatidylmuramyl peptides. |
FI803077A (en) * | 1979-10-12 | 1981-04-13 | Ciba Geigy Ag | FOERFARANDE FOER FRAMSTAELLNING AV MYRAMYLPEPTIDER |
US4406889A (en) * | 1980-02-15 | 1983-09-27 | Ciba-Geigy Corporation | Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use |
FR2498206A1 (en) * | 1981-01-19 | 1982-07-23 | Usinor | ASYMMETRICAL LEAD SHEETS AND THEIR PREPARATION METHOD |
GR78246B (en) * | 1981-01-23 | 1984-09-26 | Ciba Geigy Ag | |
US4697845A (en) * | 1985-08-02 | 1987-10-06 | The Quaker Oats Company | Long-running motor-driven baby swing |
-
1983
- 1983-07-18 EP EP83810324A patent/EP0102319B1/en not_active Expired
- 1983-07-20 DE DE19833326163 patent/DE3326163A1/en not_active Ceased
- 1983-07-21 IL IL69294A patent/IL69294A/en not_active IP Right Cessation
- 1983-07-22 NZ NZ205000A patent/NZ205000A/en unknown
- 1983-07-22 JP JP58133010A patent/JPS5933297A/en active Pending
- 1983-07-22 ZA ZA835360A patent/ZA835360B/en unknown
- 1983-07-22 AU AU17219/83A patent/AU566879B2/en not_active Expired
- 1983-07-22 IT IT48734/83A patent/IT1168778B/en active
- 1983-07-22 IE IE1728/83A patent/IE55793B1/en not_active IP Right Cessation
- 1983-07-25 BE BE0/211223A patent/BE897359A/en unknown
-
1989
- 1989-12-02 SG SG779/89A patent/SG77989G/en unknown
-
1990
- 1990-10-03 HK HK798/90A patent/HK79890A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL69294A (en) | 1987-03-31 |
EP0102319B1 (en) | 1987-08-19 |
JPS5933297A (en) | 1984-02-23 |
DE3326163A1 (en) | 1984-01-26 |
IE831728L (en) | 1984-01-23 |
IL69294A0 (en) | 1983-11-30 |
AU566879B2 (en) | 1987-11-05 |
HK79890A (en) | 1990-10-12 |
ZA835360B (en) | 1985-03-27 |
NZ205000A (en) | 1986-08-08 |
BE897359A (en) | 1984-01-25 |
SG77989G (en) | 1990-09-07 |
IT1168778B (en) | 1987-05-20 |
EP0102319A1 (en) | 1984-03-07 |
IT8348734A0 (en) | 1983-07-22 |
AU1721983A (en) | 1984-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0742714B1 (en) | Liquid pharmaceutical compositions comprising thyroid hormones | |
FI119415B (en) | A topical pharmaceutical composition containing aciclovir and hydrocortisone | |
US4476116A (en) | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption | |
HUP9901319A2 (en) | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters, use and production thereof | |
JP5785939B2 (en) | Oxazolidinone-containing dimer compounds, compositions, and methods of making and using | |
JPH03181422A (en) | Treatment of inflammation and synthetic drug for treating same | |
ES2554167T3 (en) | Methods and compositions useful in the treatment of mucositis | |
IE55793B1 (en) | Use of sugar derivatives for the prophylaxis and treatment of virus infections | |
JP3250804B2 (en) | Therapeutic peptides | |
US4548923A (en) | Muramyl peptides and processes for their manufacture | |
WO2008051502A1 (en) | Purine derivatives for the treatment of cystic diseases | |
IE59943B1 (en) | Pharmaceutical products | |
SK2697A3 (en) | Use of muramyl peptide compounds and pharmaceutical composition | |
US4263282A (en) | LH-RH-Peptides as contraceptives | |
US5334583A (en) | Use of sugar derivatives for the prophylaxis and treatment of virus infections | |
US5189017A (en) | Use of sugar derivatives for the prophylaxis and treatment of virus infections | |
US4564622A (en) | Triazole derivative as an antiviral agent | |
EP0799039B1 (en) | Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpesvirus infections | |
AU597571B2 (en) | Acylated hexose derivatives and processes for the manufacture thereof | |
US3755599A (en) | Methods for relieving bronchospasm with prostaglandin a compounds | |
RU2228195C2 (en) | Pharmaceutical composition eliciting antiviral activity with respect to herpes viruses | |
US5071836A (en) | Competitive gonadoliberin antagonists | |
NO860625L (en) | ACYLATED HEXOS DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF. | |
RU2293562C2 (en) | Using aminopurine antiviral compounds for treatment and prophylaxis of latent infections caused by herpes virus | |
RU2181049C2 (en) | Use of aminopurine antiviral compounds for treatment and prophylaxis of latent states caused by herpes virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |